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Abstract: In biological media, nanoparticles acquire a coating 
of biomolecules (proteins, lipids, polysaccharides) from their 
surroundings, which reduces their surface energy and confers 
a biological identity to the particles. This adsorbed layer is the 
interface between the nanomaterial and living systems and 
therefore plays a significant role in determining the fate and 
behaviour of the nanoparticles. This review summarises the 
state of the art in terms of understanding the bio-nano inter-
face and provides direction for potential future research and 
recommendations for future priorities and strategies to 
support the safe implementation of nanotechnologies. The 
central premise is that nanomaterials must be studied as 
biological entities under the appropriate exposure condi-
tions and that this should be implemented in study design 
and reporting for nanosafety assessment. The implications 
of the bio-nano interface for nanomaterials fate and behav-
iour are described in light of four interlinked perspectives: 
the Coating concept; the Translocation concept; the Signal-
ling concept, and the Kinetics concept. A key conclusion 
is that nanoparticles cannot be viewed as non-interacting 
species, but rather must be thought of, and studied as, bio-
logical entities, where their interaction with the environment 
is mediated by the proteins and other biomolecules that 
adsorb to them, and the key parameter to characterise then 
becomes the nature, composition and evolution of the bio-
nano interface.
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The bio-nano interface – providing a 
biological identity to nanomaterials
The role of nanoparticle interaction with biological mol-
ecules as the key to nanomedicine and nanotoxicity has 
emerged recently [1], with the development of the idea of 
the nanoparticle-protein or biomolecule corona [2]. This 
is the dynamic layer of proteins and other biomolecules 
that adsorbs to nanoparticle surfaces immediately upon 
contact with living systems and is what organisms or 
cells “see” and interact with [3]. Unlike bulk biomateri-
als, however, the fact that nanoparticles are sufficiently 
small that they can reach sub-cellular locations results in 
significant new potential impacts, specifically in terms of 
their interactions with biomolecules and biomembranes. 
The consequences of this for nanoparticle uptake and bio-
distribution and nanoparticle-induced signalling impacts 
need to be considered. A recent review of nanoparticles 
interacting with biological systems suggests that nano-
particles are mobile solids, combining the properties of 
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solids (for example, fluorescence in the case of quantum 
dots where the constituent components are non-fluores-
cent) with the ability to thermally diffuse (a property of 
molecules) [4]. Their large surface area allows them to act 
as a scaffold for protein and biomolecule binding, leading 
nanoparticles to acquire a biological identity, or a bio-
nano interface. The nanoparticle protein or biomolecule 
corona hypothesis suggests that the biomolecules (pro-
teins, lipids, nucleic acids etc.) that reside on the particle 
determine its biological identity and subsequent impacts 
[3]. The view is thus emerging that one should correlate 
the properties of the nanoparticle corona or its bio-nano 
interface to the biological activity/responses rather than 
simply the bare nanomaterial properties [5].
It is clear that the biological behaviour and conse-
quences of nanoparticles are largely dictated by how they 
interface to biology. The idea of airborne particulates 
becoming coated with lung surfactant lipid following 
inhalation was postulated in 1990 [6]. Proteins and lipids 
in lung lining liquid at the air-liquid (alveolar fluid, hypo-
phase) interface – the first biostructure an inhaled nano-
particle encounters when deposited in the alveoli – were 
later observed to coat urban nanoparticles in a corona and 
cause nanoparticle aggregation [7–9].
This lung-surfactant corona was later proposed as 
an important protective mechanism mediating the health 
impacts associated with breathing in airborne particles 
and nanoparticles in urban air [10]. Despite early evidence 
of particle coronas in the lung identified using newly devel-
oped atomic and molecular scale techniques [11], the bio-
logical interface remains the least understood aspect about 
nanoparticles, and classification systems to characterise 
the outermost layers of the bio-nano interface, i.e., those 
biological signatures that are available to engage endoge-
nous cellular machinery, are absent. By far the most studied 
component of the corona is the protein composition [7, 12], 
but lipids, sugars and other species likely also play a role 
[13–15]. Thus, despite the importance of the bio-nano inter-
face, and the fact that it potentially holds the key to both 
safe implementation of nanotechnologies and nanomedi-
cine, efforts to characterize it are surprisingly scarce [16]. 
While the focus of this review is on biomolecules such as 
proteins and lipids, the ideas are equally applicable to nan-
oparticles dispersed in environmental milieu, where decay-
ing plant and animal matter results in so-called natural 
organic matter, typically composed of polysaccharides, 
interact with nanoparticles affecting their  stability, dispers-
ability and environmental fate and behaviour [17, 18, 19].
Significant advances have been made in the last 5 
years, both in understanding of the importance of the bio-
nano interface and in terms of methods and approaches 
to study it. Evidence for this wide scale acceptance of 
the concept of the nanoparticle biomolecule corona and 
the importance of the bio-nano interface comes from the 
fact that the OECD Sponsorship Programme has included 
characterisation of nanoparticles in biofluids as part of 
their list of endpoints at the end of 2010 [20].
Before getting into the details of the state of the art and 
recommendations for moving beyond this it is important 
to note that interactions between nanoparticles and bio-
molecules, and the formation of the bio-nano interface, 
has consequences for both the nanoparticle surface itself, 
and potentially also for the proteins and other biomol-
ecules contained in the biomolecule corona. A summary 
of some of these effects, and reviews or key publications 
relating to these effects, are given in Table 1.
The emerging discipline of nanotoxicology may be 
viewed essentially as the study of the undesirable inter-
ference between man-made nanomaterials and cellu-
lar nanostructures or nanomachines [35]. In parallel, 
the considerable allure of engineered nanoparticles for 
clinical applications is due to the fact that these artificial 
Table 1 Nanoparticle-biomolecule interactions and the formation of the bio-nano interface has consequences for both the adsorbed bio-
molecules and for the nanoparticle surface and dispersion.
Effect of adsorption on Biomolecules:   Effect of interaction on Nanoparticles:
–  conformation changes → blocked or enhanced presentation 
of active sites and subsequent functional changes [21, 22]
  –  conferring a biological identity – altered interaction/uptake and 
biodistribution [23–25]
–  altered propensity for protein-protein interactions (e.g., 
fibrillation) [26]
  –  altered surface characteristics and thereby stability and dispersability 
[8, 27] and potentially also dissolution potential (as per environmental 
macromolecules such as humic acids) although limited literature [28]
–  oxidative effects – lesions, post-translational effects, 
etc. [29].
  –  reduced surface energy/reactivity [30] (possibly only temporarily)
–  depletion of medium components which can result in 
indirect toxicity effects [8, 10, 31]
  –  masking targeting or other bio-functional elements? (possibly only 
temporarily) [32]
–  altered kinetics (distribution, half-life, degradation, etc.) 
[21, 33]
  –  Altered bioactivity [23, 34]
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entities are designed to interact with biological systems at 
the nano-scale. Moreover, understanding and controlling 
the bio-nano-interface is equally important both from a 
nanomedicine and nanotoxicology point of view. In fact, 
a recent study reported that the adsorption of serum pro-
teins obscures targeting ligands grafted to nanoparticles 
(in this case: transferrin) thereby preventing targeted 
uptake, as shown schematically in Figure 1 [32]. This dem-
onstrates the importance of biomolecular interactions 
in determining nanoparticle uptake, uptake mechanism 
and fate and behavior in living systems. It is important 
to note that the size ratio between nanoparticle and pro-
teins plays a vital role in determining nanomaterial-pro-
tein (macromolecule) interactions, and indeed for many 
types of inherently small nanomaterials (e.g., Quantum 
SiO2-PEG8-TF
TfR
Different serum proteins
Figure 1 The biomolecule corona masks targeting ligands: Trans-
ferrin-functionalised nanoparticles lose their targeting capabilities 
when a biomolecule corona adsorbs on the surface. Schematic 
representation of loss of TfR targeting for Tf-conjugated nanoparti-
cles in the presence of FBS proteins (endogenous Tf, where present, 
could also compete for TfR). Reproduced from [32]. Note that the 
particles in this schematic are intended to represent ~50 nm parti-
cles, but that the nanoparticles and proteins are not drawn to scale.
dots which are typically  < 5  nm) the nanomaterials may 
be smaller than the proteins, as discussed in Klein et al. 
[36] and demonstrated by Deng et al. in their study of the 
role of gold nanoparticle size on binding to fibrinogen, 
whereby small changes in nanomaterial size (from 8 nm 
to 10–12 nm to 15 nm) resulted in significant differences 
in how the protein and nanomaterials interacted [37]. The 
schematic figures in this manuscript (taken from the lit-
erature) are not drawn to scale, but are intended only to 
illustrate the principles and concepts being described.
The fact that many endogenous transport and other 
processes utilise biomolecule clusters in the nanoscale, 
such as the lipoprotein complexes, e.g., chylomicrons 
( > 100 nm) and High Density Lipoproteins (8–10 nm), and 
ribosomes (DNA and protein clusters; 25–30 nm), suggests 
that in many cases nanoparticles may simply be recog-
nised as scaffolds onto which biomolecules can adsorb 
as part of the normal functioning of the biomolecules 
[38]. Indeed, most spherical nanoparticles studied to date 
have been shown to bind lipoproteins, often with a size 
and surface curvature influence, in addition to a composi-
tional influence, such as from surface charge [21].
Building on this background and the current state of 
the art, we suggest some potential future research direc-
tions and make recommendations for future priorities 
and strategies to ensure that the importance of the bio-
nano interface is recognised. Central to this is the fact 
that nanomaterials must be studied as biological enti-
ties under the appropriate exposure conditions, and that 
this approach must be implemented in study design and 
reporting for nanosafety assessment. The implications of 
the bio-nano interface for nanomaterials fate and behav-
iour are described from four primary perspectives:
 – the Coating concept,
 – the Translocation concept,
 – the Signalling concept,
 – the Kinetics concept.
In this paper we considered that the principles outlined 
hold for all nanoparticles types, and thus the examples 
cited from the literature may refer to metallic, metal oxide, 
carbon based, polymer coated or polymeric nanoparti-
cles, quantum dots etc. Clearly surface chemistry matters, 
as does size and shape, in terms of the finer details of how 
each different particle type behaves, but we believe that 
the principles hold generally and indeed that these could 
form the basis of a future classification strategy that is 
independent of nanomaterial composition or structure. 
The four primary perspectives presented here align well 
with, and indeed expand upon, the three “principles of 
nanotoxicology” described by Krug and Wick, namely the 
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Transport Principle, the Surface Principle and the Mate-
rial Principle [39] and focus on the role of biomolecules in 
providing a crucial interface between nanoparticles them-
selves (which are seen more as scaffolds for protein/bio-
molecule binding) and biological systems. Indeed, a key 
conclusion is that nanoparticles must be thought of, and 
studied as, biological entities, where their interaction with 
the environment is mediated by the proteins and other 
biomolecules that adsorb to them, and the key parameter 
to characterise then becomes the nature, composition and 
evolution of the bio-nano interface.
The coating concept: Interactions of 
nanoparticles with proteins, lipids, 
polysaccharides, DNA/RNA, natural 
organic matter, etc.
Scientists increasingly recognise that nanoparticles imme-
diately absorb proteins and/or other biomolecules from 
their surroundings to lower their surface free energy [40] 
with important consequences for nanoparticle stability in 
dispersion [41], and interaction with biological systems. 
Protein binding to nanoparticles changes both the hydro-
phobicity of the outermost surface (the bio-nano interface) 
and the effective surface charge, with even very positively 
charged nanoparticles typically presenting a neutral to 
slightly negative zeta potential in plasma or cell culture 
medium containing foetal calf serum. Note that for eco-
toxicological studies, natural organic matter plays much 
the same role as proteins for in vitro and in vivo toxicology 
studies, modulating the nanoparticle surface (free energy) 
and thus the dispersibility of nanomaterials [18] and inter-
action with biological systems. As a consequence, nano-
particles dispersed in biofluids containing proteins, lipids, 
polysaccharides, etc. can have a very different dispersion 
profile than the same nanoparticles dispersed in refer-
ence buffers, which can lead to very different effective or 
available doses of nanoparticles for interaction with living 
systems [3, 5]. The understanding that nanoparticles in a 
biological medium are remarkably strongly associated to 
a biomolecular layer (rich in proteins in vivo) drawn from 
their environment shifts the focus of studies and discus-
sions away from the bare material identity to a new, more 
nuanced, conception in which particle size, shape and 
corona expression (collectively the bio-nano interface) are 
more likely to be the defining features of nanomaterial bio-
logical identity and consequently fate and behaviour. Thus, 
in addition to describing the physico-chemical properties 
Nanomaterials classification and grouping
Bio-nano interactions
Coating
translocation
signalling
kinetics
Measurement principles
for NM identification in
different environments and
matrices
Identification of metrics
relevant for safety
assessment
Synthetic identity Biological identity(context dependent)
Figure 2 The importance of understanding the inter-relationship 
between the synthetic and biological identities of nanomaterials for 
hazard assessment, identification and classification of nanomateri-
als). Figure re-drawn from the NanoSafety in Europe 2015–2025 
report [43].
(the so-called “Synthetic identity”), a “biological” property 
should be added to describe the nanoparticles as they exist 
in the relevant exposure context [42], as shown in Figure 2.
The composition of the biomolecule corona, and the 
subsequent evolution as a particle moves from one biologi-
cal environment to another [44], available dose and conse-
quent biological interactions of the coated nanoparticles, 
have been found to depend on the specific details of the 
biofluid in which the nanoparticles are dispersed, which 
may account for much of the contradictory reports present 
in the literature for nominally identical materials to date 
[5]. Thus, the same (batch of) nanoparticles dispersed in 
different cell culture media (e.g., DMEM or RPMI) con-
taining identical concentrations of Foetal Bovine Serum 
(FBS) from the same batch have been shown to result in 
quite different coronas, both in terms of their thickness 
and dynamics [25]. The authors of that study observed 
that DMEM elicits the formation of a large time-dependent 
protein corona, while RPMI shows different dynamics with 
reduced protein coating. These different coronas, which 
resulted from the different ionic strengths and salt com-
positions of the media, had implications for uptake and 
impact, with the protein-nanoparticle complexes formed 
in RPMI being more abundantly internalized in cells as 
compared to protein-nanoparticle complexes formed in 
DMEM, consequently exerting overall stronger cytotoxic 
effects [25]. These results suggest that cell culture medium 
composition and ionic strength can alter adsorption of 
proteins onto the nanoparticle surface, which can impact 
on the particle agglomeration and potentially alter the 
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available dose of nanoparticles under the different expo-
sure conditions. However, in the absence of characterisa-
tion of the nanoparticles in the two different media, it is 
not possible to make any interpretation of the data on the 
basis of whether the different protein coronas result in 
different available doses, which could potentially explain 
the different observed impacts [5]. In other studies, the 
surface chemistry profiles of airborne particle samples 
collected in different continents, and exposed to the lung 
lining liquid of different subjects, showed surprising con-
sistency and resulted in similar aggregation effects [9].
Similar data resulted from comparison of corona com-
position and cellular uptake of nanoparticles dispersed in 
cell culture media containing 10% foetal calf serum that 
had either been heat inactivated (to remove the comple-
ment proteins) or not heat inactivated [24]. Here also, the 
particles with the lower protein content in their coronas 
entered cells more effectively than those with higher 
protein content in their coronas [24, 45]. Related work has 
shown that the composition of the nanoparticle biomole-
cule corona can depend on the ratio of nanoparticle surface 
area to available proteins, with the consequence that nano-
particle coronas prepared under conditions typical for in 
vitro testing (i.e., 3%–10% serum proteins in medium) may 
not be representative of the corona that would form under 
in vivo conditions (typically 55%–80% proteins) [30].
A study of the interaction of nanoparticles with sur-
factant protein A (SP-A), a significant protein component 
of alveolar lining fluid, found different particle-protein 
interactions for each of eight different nanoparticles [46]. 
Interestingly, three variants of the same material (cerium 
dioxide nanoparticles) revealed different adsorption pat-
terns despite the materials being nominally identical and 
indistinguishable in electron microscopy images [46]. 
This suggests that the biomolecule corona composition, or 
the details of the bio-nano interface, could be a very sen-
sitive tool to distinguish subtle material differences and 
to predict biological impacts, once correlations between 
adsorbed biomolecules and signalling or other effects are 
confirmed. In contrast, surfactant protein D (SP-D) alters 
cellular uptake in a different way [47].
Multiple studies have assessed the effect of nanoparti-
cle composition [38, 48, 49], size [49, 50], surface coating 
[51, 52], shape and other physico-chemical parameters on 
the nature and composition of the protein corona. Recent 
reviews have attempted to summarise the many factors 
that have been found to influence protein–nanoparticle 
interactions [53, 54], and have described these factors as 
falling into three categories: protein (or macromolecule)-
related (molecular weight, isoelectric point (pI), and 
conformational flexibility), NM-related (species, size, 
shape, charge, roughness, hydrophobicity, crystallization, 
defects, and functionalization), and medium-related (pH 
and ion strength) [54].
In the case of nanoparticles dispersed in the environ-
ment, interaction with environmental organic matter and 
biological molecules has been shown to determine their 
subsequent effects and fate in a similar manner. Some 
studies have shown that nanoparticles can adsorb natural 
organic matter to form complexes and, as a consequence of 
such coating, they may become negatively charged, alter-
ing their fate and transport in the aqueous environment 
[55, 56]. Humic acids are a major part of the natural organic 
matter contained in soil and fresh water. Their structure, 
which consists of a skeleton of alkyl/aromatic units cross-
linked mainly by oxygen and nitrogen groups with the major 
functional groups being carboxylic acid, phenolic and alco-
holic hydroxyls, ketone and quinine groups, allows them to 
behave as surfactants, with the ability to bind both hydro-
phobic and hydrophilic materials [57]. As a consequence of 
this behavior, nanoparticle-humic acids interactions should 
be a factor of relevance in the study of the life cycle of nano-
materials, and likely natural organic matter plays a similar 
role in the environment that proteins do for human health.
We thus propose that it is vital that nanomaterials be 
considered as biological entities, and studied as such.1 Key 
steps in the short to medium term include understanding 
and eventually predicting which chemical, geometrical 
and physico-chemical parameters of nanomaterials lead 
them to preferentially adsorb which proteins, and con-
necting the absorbed proteins with observed impacts, 
such as uptake, localization and signaling. For example, 
the role of opsonins and dysopsonins is well understood 
in terms of phagocytic recognition [58, 59]. However, 
much work is required to tease out the signaling pathways 
influenced by biomolecules contained at the bio-nano 
interface, whether these be functioning normally or expe-
riencing altered functionality as a result of conformation 
changes induced by binding to the surface.
The translocation concept: 
 interactions of nanomaterials with 
cells, tissues, barriers, etc.
The human body has four portals of entry for nanoparti-
cles: three natural portals, the lung, the digestive tract and 
1 http://www.skep-network.eu/Libraries/Network_ documents/
SKEP_Nanomaterials_in_REACH_Report.sflb.ashx.
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the intact skin, and one artificial portal, the veins, into 
which nanoparticles can be injected. It has been shown 
that nanoparticle translocation into capillaries leads to 
their translocation into other organs [60–65], and evidence 
is emerging that the route of entry, and the biomolecules 
that form the initial corona at the site of entry (e.g., plasma 
proteins following injections versus lung surfactant pro-
teins following inhalation), play a distinct role in deter-
mining the organ biodistribution of nanoparticles [66]. For 
example, accumulation of TiO2 nanoparticles in the brain 
was 100-fold higher for particles entering via lung than 
for those injected directly into the bloodstream (Person-
nal Communication W.G. Kreyling). Further evidence for 
the importance of the initial bio-nano interface, which is 
determined by the route of exposure, comes from a study 
of the interaction of magnetite nanoparticles (110–180 nm 
in diameter), coated with different polymers (starch, car-
boxymethyldextran, chitosan, poly-maleic-oleic acid, 
phosphatidylcholine), with alveolar macrophages [67]. 
Cellular binding and uptake of nanoparticles by alveolar 
macrophages was increased for nanoparticles treated with 
SP-A, whereas albumin, the prevailing protein in plasma, 
led to a significant decrease. This study provides evidence 
that, after inhalation of nanoparticles, a different protein 
coating and thus different biological behavior may result 
compared to direct administration to the bloodstream [67].
A direct effect of biomolecule corona composition 
on nanoparticle biodistribution has been shown in an 
elegant study using radiolabelled gold nanoparticles of 
five different sizes (1.4, 5, 18, 80, and 200 nm) and 2.8 nm 
gold nanoparticles with opposite surface charges fol-
lowing intravenous injection into rats [68]. Results indi-
cated that both size and surface charge of nanoparticles 
strongly determined the biodistribution, with different 
charge particularly leading to significantly different 
accumulations in several organs. The authors concluded 
that the alterations of accumulation in the various organs 
and tissues, depending on nanoparticle size and surface 
charge, were mediated by dynamic protein binding and 
exchange [68].
When interacting with cells, nanomaterials come 
into close contact with the cell membrane, a dynamic 
structure that segregates the chemically distinct intra-
cellular milieu (the cytoplasm) from the extracellular 
environment by coordinating the entry and exit of small 
and large molecules. Macromolecules are carried into 
the cells in membrane bound vesicles derived from the 
invagination and pinching-off of pieces of the plasma 
membrane to form endocytic vesicles. This process, 
termed endocytosis, has different features depending on 
the size and type of the molecule/structure internalized: 
receptor-independent endocytosis (fluid-based endo-
cytosis and macropinocytosis), and several types of 
receptor-dependent endocytosis (clathrin-dependent, 
lipid-raft-independent, lipid raft-dependent/caveolae-
independent, and caveloae-dependent). These endog-
enous processes are exploited by bacteria and viruses 
for invading cells, and it is likely that also nanoparticles 
may enter cells through them, although there are quite 
conflicting reports as to the exact mechanism(s) medi-
ating cell entry by different nanoparticles [69–72]. Very 
likely this is a result of different bio-nano interfaces. 
A recent review of cellular uptake of nanoparticles 
describes work revealing active endocytosis mechanisms 
and pathways involved in their cellular uptake, and 
summarises the current state of knowledge: Interested 
readers are referred here for more details [73]. All endo-
cytic pathways have a feature in common, in that the 
particle, which entered the cell, is finally located in an 
intracellular vesicle, typically the lysosome, as the final 
sub-cellular destination [74–76]. However, there are 
studies, which reported the intracellular localization of 
nanoparticles that were not membrane bound, suggest-
ing alternative pathways for particles to enter, or that the 
nanoparticles can escape the endosomes, as a result of 
endosomolysis [77–80]. This alternative way of nanopar-
ticle penetration into cells, i.e., through the cell mem-
brane, has been called “adhesive interaction” (by van 
der Waals and other forces) and has been suggested as 
an alternative mechanism of passive entry [81]. Another 
recent publication offers convincing evidence for a 
passive mechanism whereby nanoparticles enter cells 
by membrane penetration on an experimental and cal-
culation basis [80]. The fact that nanoparticles are found 
free in the cytoplasm following uptake via the adhesive 
mechanism is noteworthy, since free nanoparticles in the 
cytoplasm may cause cellular effects different from those 
contained in vesicles (which entered the cell probably 
by an endocytic mechanism). Moreover, the intracellu-
lar trafficking may be different and also interaction with 
intracellular structures like the cytoskeleton, the orga-
nelles and the nucleus may be via direct contact for free 
nanoparticles. These aspects may all contribute to the 
different reactions of the cell to different nanoparticles, 
and are worthy of further investigation.
Very significant modulatory effects of proteins and 
the bio-nano interface have been observed in terms of 
nanoparticle uptake by human macrophages, by undiffer-
entiated and by PMA-differentiated monocytic THP-1 cells 
of 50 nm and 100 nm fluorescently-labelled carboxyl- or 
amine- modified polystyrene nanoparticles from medium 
with and without (serum free medium) serum proteins 
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[59]. The amount of internalized nanoparticles, the uptake 
kinetics, and its mechanism were critically dependent on 
particle opsonization by serum proteins, with nanoparti-
cles being rapidly internalized by cells in serum-free (SF) 
medium until they reached saturation kinetics, whereas 
in 10% human AB serum-enriched (SE) medium the nano-
particle uptake rate was drastically reduced as the uptake 
was via receptor-mediated processes [59]. Thus, in terms 
of understanding nanoparticle uptake and biokinetics, 
the bare material surface is clearly the wrong parameter 
to use, and indeed uptake studies in the absence of an 
appropriate biomolecule environment report on uptake as 
a result of membrane damage in an artefactual situation 
[34], rather than on nanoparticle uptake utilising endog-
enous pathways.
However, one important question that remains to 
be answered is whether the protein and biomolecule 
layer on the nanoparticle surface mediates the binding 
to cells through one or more specific active mechanisms 
or via non-specific interactions, whereby the biomol-
ecules behave as a simple coating which reduces the 
surface energy of the nanoparticles. There are consider-
able differences in interpretation in the literature to date 
regarding uptake mechanisms, and approaches such as 
poisoning the endocytic receptors using pharmacologi-
cal inhibitors or silencing of selected proteins involved 
in specific endocytic pathways (e.g., clathrin or caveolin) 
suggest that the same nanoparticle might exploit differ-
ent uptake mechanisms to enter different cell types or 
indeed the same cell type under different conditions [82]. 
Similar results have been reported for nanoparticles engi-
neered for targeting the folate receptor: folate receptor-
specific siRNA was used to reduce folate receptor levels 
and uptake of heparin-folate-paclitaxel nanoparticles by 
target cells, but silencing only reduced uptake to half of 
its value in the control cells, suggesting multiple path-
ways of uptake [72]. A recent study of differently surface 
modified 100  nm polystyrene nanoparticles indicated 
that different specific protein coronas did not result in dif-
ferential association of the particles to endothelial cells, 
suggesting that binding and cellular uptake by these cells 
may not be triggered by interaction of the protein corona 
with specific receptors [83]. The authors suggested that 
an assessment of the adsorptive capacity of nanoparticles 
could be useful in order to predict the magnitude of nano-
particle cellular interactions. Much of the success to date 
in terms of nanoparticles for drug delivery has been the 
result of fortuitous absorption of endogenous transporter 
proteins, such as Apolipoprotein E, to nanoparticles, or 
deliberate functionalisation of nanoparticles with these 
proteins [84, 85].
Once it is recognised that the biointerface is the key 
parameter to understand in terms of determining mecha-
nisms of uptake of nanomaterials, a key question becomes 
how researchers can target nanoparticles to best utilise 
these pathways, and simultaneously avoid non-specific 
protein interactions, by designing the bio-nano inter-
face. Several recent reviews highlight the various endog-
enous uptake pathways available to nanomaterials, and 
examples of therapeutic strategies that could potentially 
utilise these pathways [86, 87]. Indeed, there has been 
considerable effort devoted to development of targeting 
nanoparticles, such as conjugation of 100-nm polysty-
rene nanoparticles with glycocalicin, which significantly 
increased the particle adhesion on P-selectin-coated sur-
faces and cellular uptake of nanoparticles by activated 
endothelial cells under physiological flow conditions [88], 
or functionalisation of cerium oxide nanoparticles with 
transferrin (Tf), to increase preferential uptake by trans-
ferrin receptor (TfR) over-expressing human lung cancer 
cells (A549) and normal embryo lung cells (WI-38) [89]. A 
key finding from this work is that the strength of interac-
tion between the nanoparticles and the targeting protein 
(Tf in this case) can be tuned by modifying the surface 
charge of the nanoparticles, and that binding energy 
values could be correlated with cellular uptake (as shown 
schematically in Figure 3) [89], in a first step towards 
quantitative structure-activity relationships (QSARs).
The task of modeling, and ultimately predicting, 
the distribution and fate of nanoparticles represents an 
interesting, and quite new challenge [76]. A flux-based 
approach, based on live cell imaging of fluorescent 
nanoparticle uptake and transport in a time resolved 
manner has shown that the nanoparticles rapidly local-
ize to endosomes (1 h) and later to lysosomes (by 4 h), 
with no evidence of nanoparticles exiting from lys-
osomes once they have arrived there [76]. The observed 
decrease in fluorescence over time was shown to corre-
late with cell division, and with the nanoparticle load 
being split evenly between the two daughter cells. While 
vesicle recycling is a normal part of cell homeostasis, no 
recycling of fluorescent nanoparticles from vesicles was 
observed in the above study [76]. Indeed, another study 
has shown that relatively few 40 or 100 nm carboxylic-
modified polystyrene nanoparticles are able to access 
endocytic recycling pathways, as judged by the lack of 
significant co-localization with Rab11, a key protein asso-
ciated with recycling vesicles [90]. There is no evidence 
that corona-driven export processes exist for nanoparti-
cles (unless specifically engineered to express an export 
signal – such as transferrin, as described below), and the 
chances of the appropriate specific intracellular corona 
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arising from non-specific protein binding during uptake 
are slim, [76] although potentially such signals could 
arise as a result of the nanoparticles binding peptides 
from the antigen processing pathways. Clearly there are 
some exceptions to this general rule in the case of spe-
cialized cells such as biological barriers, where trans-
location is a key function, such as the air-blood tissue 
barrier and the mucosal barriers where particle trans-
cytosis, by epithelial and endothelial cells separated by 
the fused basement laminae of the two cells is common 
though a selective mechanism [60]. The penetration of 
nanoparticles through a cell (into and out, membrane 
bound) is called transcytosis or cytopempsis.
Single-walled carbon nanotubes (SWNT) were 
observed to undergo exocytosis in NIH-3T3 cells, the exo-
cytosis rate closely matching the endocytosis rate with 
negligible temporal offset [91]. The exocytosis pathway 
was illustrated by superimposing example particle trajec-
tories recorded in the near infrared onto the correspond-
ing optical image of different cells [91]. Tf, which has a 
well-known recycling pathway, has been shown to induce 
exocytosis of gold nanoparticles to which it is physically 
adsorbed at a rate that was in linear correlation with 
the nanoparticle size [92]. Fifty nm was reported as the 
optimal cellular accumulation size for Tf-gold nanoparti-
cles, due to the equilibration of the rates of uptake and 
exocytosis [92].
The signalling concept: interaction 
of nanoparticles with major intra-
cellular chemical systems
The range and amount of nanoparticles humans are 
exposed to is quite significant (particularly from com-
bustion), with the increasing production of engineered 
nanomaterials now contributing to this. The occupational 
setting is now considered as the most likely exposure 
route to engineered nanoparticles, but medical formula-
tions may result in a wider population exposure [12]. The 
contribution of exposure to ultrafine particles such as 
those from combustion processes, to respiratory and skin 
diseases as well as more insidious and complex patholo-
gies such as cancer and cardiovascular dysfunction, is 
now becoming apparent [93–95]. Their cumulative effects, 
or more likely the knock-on effect to neighbouring cells as 
well as more distant tissues and organs (i.e., paracrine sig-
nalling and cell activation) plays a key role in their toxicity 
at the systemic level.
A key question to consider at the outset is whether 
nanoparticles “signal” or merely perturb signalling path-
ways? Clearly sophisticated nanoparticles envisioned for 
biomedical applications may “signal” according to their 
deliberate functionalization and/or cargo of signalling 
molecules/drugs/genes, but it is important to consider 
Tf-CNP interaction is tunable
Tf-CNP-cell multi-point interaction
Cells with TfRs on surface
Non-specific interaction CNPs with cells
Tunable interaction
Tu
na
ble
 
int
er
ac
tio
n
CN
Ps
 
int
er
ac
tio
n 
w
ith
 
ne
ga
tiv
ely
 ch
ar
ge
d T
f
P
artially fixed and partially
tunable
 interaction
TfR
 m
ediated
 interaction
 of
 Tf:CNPs with cells
Cellular
uptake
CNPs
with positive
or negative
surface charge
Cells
with TfRs
on surface
Tf
conjugated
CNPs
Tf-TfR interaction is fixed
TfR
Tf:CNPs
CNPs
Tf
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whether other, pristine or non-functionalized nanopar-
ticles “signal”. The main thesis in the present review is 
that nanoparticles can signal by virtue of their acquired 
bio-corona of proteins, lipids, sugars, or other biomol-
ecules and that studies conducted to date have not fully 
taken into account the “biological” identity of nanopar-
ticles. There are certainly some (very few) examples of 
nanoparticles that appear to signal per se as a function 
of their specific size, for instance, the finding that single-
walled carbon nanotubes (SWNTs) constitute a new class 
of universal K+ channel inhibitors that hamper channel 
function by fitting into the pore and thus either hindering 
ion movement or alternatively preventing further confor-
mational steps [96]. We believe that further studies, using 
systems biology approaches, may uncover more examples 
of nanoparticle-mediated signaling at doses of nanoparti-
cles that are more realistic, and that the bio-corona and, 
hence, the bio-nano-interface is likely to be an important 
determinant of such signaling. This is in distinction to the 
vast majority of publications to date which apply exces-
sive amounts of nanoparticles to cells and which focus 
only on crude measurements of cell death.
Mapping the research agenda for investigating nano-
particle signalling effects, the research objectives can be 
broken down into three interlinked levels. Firstly, nano-
particles attached to the cell surface (cell membrane) may 
trigger a cascade of signalling processes into the cell and 
throughout the cell. A key question which one should ask 
is whether nanoparticles need to enter a cell in order to 
trigger/cause any effects inside the cell. While researchers 
have long been concerned about distinguishing between 
nanoparticles taken up into cells versus those adhered 
to the membrane for quantification of uptake [76, 97], 
less research has been directed to understanding nan-
oparticle-induced signalling from the cellular surface, 
which is a critical knowledge gap at present although 
several groups are now working on this and publications 
addressing this topic will appear in the literature in the 
near future [Personnal Communications from H. Hofmann 
(EPFL) and K.A. Dawson (UCD)]. Secondly, nanoparticles 
can signal once they are inside single cells. Here, impor-
tant aspects that need to be addressed are the manner in 
which nanoparticles bypass the cell membrane, enter into 
the cell, localise to the mitochondria and other organelles 
and finally the nucleus, causing changes in phenotypic 
function and the activation of distress signals in the form 
of pro-inflammatory or other molecules. The third signal-
ling level includes the pathways by which cells commu-
nicate their response to interaction with nanoparticles to 
neighbouring cells and then to more distant tissues and 
organs through soluble mediators. A limited number of 
studies demonstrate paracrine signalling from nanopar-
ticles in cells to other non-exposed cells, suggesting that 
such effects may occur [98–101].
At present, much of our understanding of nanoparti-
cle induced alterations of signal transduction is limited to 
a very small space and time window. The question of how 
these adaptive signals are propagated to and translated 
by remote tissues and organs, how the internal milieu is 
modulated by them, and the signalling pathways involved 
in the translocation of nanoparticles from their point of 
uptake to distant tissues have not yet been addressed. 
Much of what we know of the integrative pathophysiology 
of engineered nanoparticles comes from animal studies 
focused on translocation and bioaccumulation [68, 102]. 
Translating the results to humans is not straightforward, 
and as several studies on drug toxicity have shown, 
caution needs to be exercised when extrapolating results 
from animal models to human physiology, pathology or 
toxicity [103]. Moreover, animal models are not amena-
ble to decomposition of signalling dynamics in differ-
ent tissues and organs. Additionally, given the degree of 
redundancy in signalling pathways, decoupling effects of 
biomolecules bound to nanoparticles from those of their 
unbound counterparts will be challenging. However, 
systems biology approaches are making significant strides 
here [104–106].
The induction of oxidative stress is commonly viewed 
as a unifying concept for understanding the cytotoxic 
effects of nanoparticles, such as nano-sized metal parti-
cles and their oxides as well as those produced by com-
bustion (including from motor vehicles) [107]. However, 
it is also important to assess whether “oxidative stress” 
is merely a secondary event resulting inevitably from dis-
ruption of biochemical processes and the demise of the 
cell, or a specific, non-random event that plays a role in 
the induction of cellular damage, e.g., apoptosis? For a 
further discussion of these issues, readers are referred to 
Shedova et al. [108]. The mechanism by which oxidative 
damage occurs appears to be via the inhibition of elec-
tron transfer in the TCA (tricarboxylic acid) cycle and the 
consequent accumulation of TCA cycle intermediates. 
The TCA cycle is an essential metabolic network in all 
oxidative organisms and provides precursors for anabolic 
processes and reducing factors (NADH and FADH2) that 
drive the generation of energy. Reactive oxygen species 
(ROS) are formed in the mitochondria during respiration. 
It has been shown that a healthy metabolic network plays 
a key role in the defense against oxidative stress through 
the production of enzymes and electron acceptors which 
participate in the detoxification of ROS [109]. Interfer-
ence in the mitochondrial cycle results in oxidative stress 
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owing to an increase in ROS, which act as second messen-
gers to induce a cell reaction that may eventually lead to 
cell death. How nanoparticles cause oxidative stress and 
subsequent apoptotic or necrotic signalling is not clearly 
understood, and furthermore the process is unlikely to 
be the only mechanism by which nanoparticles cause 
cell and tissue damage [110]. Probing signalling mecha-
nisms at the cellular level should focus on delving into 
the mechanisms of ROS production by nanoparticles 
upon entering cells, and subsequent cellular adaptation 
at the nuclear level (changes in gene expression) (Figure 
4). It may be worth considering whether the develop-
ment of oxidative stress could be a first (unspecific) reac-
tion mechanism to foreign material intrusion. In fact, a 
short-lived reaction is compatible with a normal innate 
defensive response, which resolves rapidly with limited 
cell damage that is readily repaired. On the other hand, 
the persistence of the reaction could lead to significant 
damage from apoptosis and genotoxicity, and eventually 
to cancer. Thus, understanding the origin and kinetics of 
the oxidative stress induced by nanoparticles and corre-
lating it to pathological risk could provide vital insights 
in the future as to the impacts of nanomaterials. Note that 
this theme of transience or duration of response is picked 
up in the “kinetics concept” section, as full understand-
ing of mechanisms will only be possible with a proper 
emphasis on rate and kinetics of the various biological 
processes.
A detailed investigation of the mechanism of toxicity 
induced by 50 nm amine-modified polystyrene nanopar-
ticles following uptake by 1321N1 brain astrocytoma cells 
found that the nanoparticles are localized in lysosomes, 
whereupon the lysosomal membrane becomes destabi-
lized, likely because of the nanoparticle’s positive charge, 
leading to release into the cytoplasm of both nanoparti-
cles and proteolytic enzymes such as cathepsins [112]. 
This, in turn, results in damage to the mitochondria and 
activation of caspases 3 and 7, with consequent cleavage 
of PARP-1, ultimately resulting in the apoptotic death of 
the cells [112]. Ongoing work has shown that the kinetics 
of the lysosome membrane damage can be correlated with 
the digestion of the nanoparticle protein corona in the lyso-
somes which allows the underlying amine groups on the 
nanoparticles to be re-exposed [113]. Smaller, fully ami-
nated, dendritic polymer nanoparticles have been seen 
to cause endosomolysis prior to transfer to lysosomes, 
however, and have been seen to be later localized in the 
mitochondria. In both stages, oxidative stress has been 
seen to give rise to activation of caspases, inflammatory 
responses and subsequent apoptotic (and other kinds of) 
cell death [79, 114].
An important advance in understanding nanopar-
ticle-induced signalling and toxicity has been achieved 
utilising an integrated proteomics approach, as routinely 
used to identify protein interaction pathways, to identify 
the toxicity pathways and networks that are associated 
Figure 4 Left: Critical aspects of intracellular signalling: mechanisms of nanoparticle (ENP) entry, ROS induction, nuclear damage and ENP 
fate after cellular reaction (or death). Right: Protein interacting network 1. This representative network of differentially expressed proteins 
shows the protein inter-relationships and relevant signalling pathways. Two major sub-networks within the network are centered by NF-κB 
and YWHA2. Proteins in pink are up-regulated while proteins in green are down-regulated. Solid lines represent direct relationships. Dotted 
lines represent indirect relationships. Lines connecting the proteins indicate known inter-relationships from the IPA database. From [111]. 
Whether, in this particular case the impacts can be best described as “signalling” or “perturbation of signalling” pathways is open to 
debate, but the possibility that that signalling may take place at the bio-nano-interface and as such needs to be considered in the design, 
and interpretation, of nanosafety and nanointeraction studies is one the main messages of the present review.
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with exposure of human bronchial epithelial cells to 
nanoscale titanium dioxide [111]. Utilizing 2-DE and MS, 
46 proteins that were altered at protein expression levels 
were identified and mapped, using Ingenuity Pathway 
Analyses™ (IPA) canonical pathways and Ingenuity 
Pathway Analyses tox lists, to create protein-interacting 
networks and proteomic pathways. This provided the 
first preliminary protein-interacting network maps and 
may give novel insights into the biological responses 
and potential toxicity and detoxification pathways of 
titanium dioxide [111]. However, as with many early 
studies in an emerging field, there are some concerns 
regarding how much can be interpreted from this study 
which lacked appropriate controls [e.g., no bulk TiO2 or 
other (reference) material has been used for compari-
son]. Another example of this approach uses proteomic 
techniques including two-dimensional electrophoresis/
mass spectrometry and protein microarrays to study 
the differentially expressed proteome and phosphopro-
teome, respectively [115]. Here, systems biology analysis 
of the data revealed that unfolded protein-associated 
endoplasmic reticulum (ER) stress response was the 
predominant event in response to the presence of gold 
nanoparticles [115].
An alternative route to inflammation, directly linked 
to protein conformation and presentation at the bio-nano 
interface, has recently been suggested by Deng et al. [116]. 
Their study demonstrated that negatively surface charged 
nanoparticles can unfold fibrinogen and that the binding 
of fibrinogen to poly(acrylic acid) coated gold nanoparti-
cles of 5 nm leads to interaction with the Mac-1 receptor 
and its activation, leading to a cytokine response through 
degradation of IκB, subsequent release of NF-κB and its 
translocation to the nucleus. Since plasmatic fibrino-
gen has been reported to bind many different types of 
nanomaterials, including the metal oxides SiO2 and TiO2 
[117], the authors proposed that fibrinogen-bound nano-
particles are potentially pro-inflammatory. Note that, 
as indicated above for oxidative stress, activation of an 
inflammatory pathway does not necessarily correspond to 
toxicity, but is rather a defensive reaction and may cause 
no overt damage if transient, and thus an understanding 
of the kinetics and duration of the response to nanoparti-
cles is vital.
An elegant approach to assessing nanoparticle 
impacts has been to look at the effect of citrate-reduced 
gold and silver nanoparticles on primary cultures of 
murine adrenal medullary chromaffin cells [118]. Car-
bon-fiber microelectrode amperometry examination of 
exocytosis in nanoparticle-exposed cells revealed that 
nanoparticle exposure lead to decreased secretion of 
chemical messenger molecules, of up to 32.5% at 48 h of 
gold nanoparticle exposure. Repeated stimulation of exo-
cytosis demonstrated that these effects persisted during 
subsequent stimulations, meaning that nanoparticles do 
not interfere directly with the vesicle recycling machinery 
but also that cellular function is unable to recover follow-
ing vesicle content expulsion [118]. Similar results were 
also observed in mast cells [118].
Beyond the level of the single cell, the means by 
which injured cells communicate their distress causing 
systemic and long-term damage is therefore a critical 
issue. The adaptive response of nanoparticle-injured cells 
is an over production of H2O2 with the consequent genera-
tion of free radicals and the secretion of pro-inflamma-
tory cytokines [119]. Recapitulating the systemic effects of 
nanomaterial toxicity in vitro requires properly scaled in 
vitro and computational models so that the consequences 
of localized nanoparticle induced injury to the whole 
body response can be systematically investigated. Cell-
cell signalling, and signal propagation across the foetal 
barrier has recently been shown as the toxicity mecha-
nism by which CoCr alloy metal nanoparticles induce a 
novel type of indirect genotoxic effect across cellular bar-
riers [98, 120]. The CoCr nanoparticles were observed to 
cause DNA damage and tetraploidy in cells not directly 
exposed to the nanoparticles [98], i.e., on the other side 
of the barrier in an in vitro model system, without a sig-
nificant passage or leakage of metal through the barrier. 
Such cell-cell signalling is protein mediated, and likely 
triggered by something present on the nanoparticle 
surface that interacts with cellular receptors, or induces 
signalling from lysosomes.
It is a fair criticism of the field to date that the major-
ity of studies published have utilised unrealistically high 
doses of nanoparticles and that the “toxic effects” that 
have been reported, and the assays used to detect these 
effects, lack the sophistication that is needed to fully 
appreciate potential nanoparticle-induced signalling 
events. However, this current lack of evidence for nano-
particle-induced signalling impacts is also a consequence 
of the fact that systems approaches are only beginning 
to be applied to these issues, and research to address 
this issue is underway. Data demonstrating nanoparti-
cle induced signalling from nanoparticles located at cell 
membranes, from nanoparticles taken up into cells, and 
from nanoparticle-exposed cells to neighbouring cells will 
soon begin to appear in the literature as this convergence 
of nanosafety maturing as a discipline and more wide-
spread application of systems biology approaches reaches 
fruition [Personnal Communications from H. Hofmann 
(EPFL) and K.A. Dawson (UCD)].
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Connecting the nature of the bio-nano interface with 
downstream signalling impacts will be important in 
teasing out potential longer term consequences of expo-
sure to nanomaterials, and to correlating impacts to the 
composition of the bio-nano interface and the underlying 
nanoparticle physico-chemical properties.
The Kinetics concept: Timescales 
of interaction of nanoparticles with 
biomolecules and cells
A deep understanding of the biological effects of nano-
particles requires knowledge of the equilibrium and 
kinetic binding properties of proteins (and other biomol-
ecules such as lipids and polysaccharides) that associ-
ate with the particles, and especially under competitive 
binding conditions, such as those occurring in vivo [1]. 
The rates by which different proteins bind to and disso-
ciate from nanoparticles, i.e., the time scales on which 
particle-associated proteins exchange with free proteins, 
are critical parameters determining their interaction 
with receptors, and biological responses generally. The 
biological outcome may also be different, depending on 
the relative exchange rates of proteins with nanoparti-
cles and cellular receptors, respectively [3]. In addition, 
the particle-bound protein may have altered exchange 
rates with a cellular receptor. It is clear that, in under-
standing how particles will interact with cells, these 
issues, currently almost unstudied, are amongst the most 
fundamental. Additionally, the corona may not imme-
diately reach equilibrium when exposed to a biological 
fluid, and will evolve as the nanoparticle encounters new 
milieu, for example, when particles redistribute from one 
compartment or organ to another, such as upon receptor-
mediated endocytosis from the extracellular environment 
into the primary endosomal cavity, or from the cytosol to 
the nucleus [44].
In addition to understanding the kinetics of forma-
tion of the corona and its evolution during nanoparti-
cle uptake and translocation, it is vital to understand 
the fate of both the nanoparticle corona and the nano-
particles themselves in their final sub-cellular loca-
tions. In particular, there is emerging evidence that 
the bio-nano interface can be degraded upon localisa-
tion of the nanoparticles in endosomes or lysosomes 
[113], and indeed even that some nanoparticles them-
selves, including carbon nanotubes, may degrade in 
situ in cells or in vivo [121]. Using fluorescently labelled 
proteins in the nanoparticle corona, it has been possible 
to track nanoparticle localisation and corona digestion 
and to correlate this with the toxicity impacts observed 
[113]. Using amine-modified polystyrene nanoparticles, 
a detailed event sequence has been tracked showing 
how nanoparticle location and biological responses 
are connected – nanoparticles are localised in the 
lysosomes undergo acid-degradation of the corona, 
leading to re-expression of the positive charge on the nan-
oparticles, which were previously masked by the pres-
ence of the protein corona, and consequently disruption 
of the lysosomal wall, leading to a complex set of signal-
ling responses [113]. For aminated dendrimers, a clear 
generation dependence is observed, reflecting the sys-
tematic increase in the number of surface amino groups, 
implying a similar digestion in the endosomes [79].
The ultimate goal of nanosafety assessment is to be 
able to correlate the uptake rate, localisation and actual 
sub-cellular dose with the kinetics of the onset and prop-
agation of the impacts observed. This requires a good 
understanding of the timing of signalling events that 
various assays report on, to ensure that experiments are 
designed with appropriate time-points such that desired 
effects can be observed. This is especially important 
for transitory or late-onset impacts, or for impacts that 
are down-stream of the initial signalling impacts. Cel-
lular responses may not be linear with dose, however, 
and the process of saturation should be understood. 
Equally, understanding the intrinsic cellular protection 
mechanisms through antioxidants is critical to differ-
entiating between responses of different cell types. To 
fully understand the impacts of different nanomaterials, 
it is important to identify the relevant cascade pathways 
and to link the rates of response to the physico-chemical 
properties of the nanoparticles, to their different bio-
nano interfaces, and to the intrinsic characteristics of 
the cell-lines. For all processes, the rate of response is 
the most important characteristic parameter, and rel-
evant rates include:
1. Uptake rates (endocytosis, adhesive interaction) and 
connection to bio-nano interface composition
2. Impact rates of membrane bound vs. free nanoparticles
3. Signalling rate of nanoparticles attached to cell 
surface – identification and quantification of most 
relevant signalling markers at each time point
4. Rate of recovery of relevant signalling markers at each 
time point
5. Rate of ROS generation
6. Endosomolysis thresholds and rates
7. Rates of trafficking/translocation to other organelles 
(mitochondria, nuclei) and/or trancytosis
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8. Uptake rates and size thresholds for organelles 
(mitochondria, nuclei)
9. Identification of impact pathways and rates (including 
activation/expression of relevant signalling proteins)
10. Identification of types and kinetics of cell-cell 
signalling impacts
11. Identification of kinetics of evolution [122] and 
degradation of the bio-nano interface [114] and the 
underlying nanoparticle degradation both prior to 
uptake (i.e., in the exposure media and the influence 
of media composition on nanoparticle degradation 
rate for example [28]) and following uptake (for 
example in the lysosomes). As recently suggested by 
Shannahan et al. [123], the corona may only degrade 
after lysosomal localisation (of silver nanoparticles) 
resulting in acid-mediated oxidation and ultimately 
cell death due to toxic metal ions. Indeed corona 
degradation in the lysosomes has recently been 
demonstrated utilising loss of fluorescence signal 
from fluorescently-labelled serum proteins bound 
to nanoparticles over time [113]. Thus, elucidating 
the role of the bio-nano interface in modulating the 
ionic dissolution of metal and metal-oxide based 
nanoparticles is of particular importance given the 
widespread role of these materials in medicine.
Coupled with this is a requirement to understand in 
detail where nanoparticles are located, in order to cor-
relate impacts with particle localisation. Significant 
progress to this end has been achieved, and indeed it 
is now possible to use cellular proteins associated with 
the different vesicular structures of cellular uptake path-
ways to report on kinetics of nanoparticle uptake and 
localisation. Thus, 40  nm carboxyl-modified polysty-
rene nanoparticles were shown to first pass through an 
early endosome intermediate decorated with Rab5, but 
to rapidly transfer to late endosomes and ultimately lys-
osomes labelled with Rab9 and Rab7, respectively [90]. 
Larger nanoparticles of 100  nm diameter also reach 
acidic Rab9- and Rab7-positive compartments although 
at a slower rate compared to the smaller 40 nm nanopar-
ticles [90]. This information can then be coupled to the 
kinetics of signalling impacts induced following locali-
sation, and using co-localisation approaches, to qualify 
particle amounts in the various compartments. Thus, 
it is possible that upon entering of foreign material, 
orchestrated defence processes are initiated by the cell, 
depending on the nature of the nanoparticle corona, and 
that concentration of nanoparticles, impact time and 
reaction time would have to be considered as part of a 
kinetics-based modelling approach.
Alternative routes towards nanoparticle track-
ing include Raman spectroscopy. The use of Surface 
Enhanced Raman Scattering from gold nanoparticles and 
nanoaggregates to probe the environment of the subcel-
lular compartments through which they are trafficked has 
been demonstrated [124, 125]. This approach also dem-
onstrated the use of molecular labelled nanoparticles as 
more specific probes of the local environment [126–128]. 
However, the uptake rates and mechanisms as well as the 
subsequent trafficking may be specific to the nanoparti-
cle type, size and surface chemistry. More recently, Raman 
spectroscopy has been employed to identify and localise 
unlabelled polystyrene nanoparticles in cells in vitro [129].
What can we learn from viral 
bio-nano-interfaces and their 
dynamics?
Nanoparticles and virus particles share many features, 
including size range. Independent of their nature, adhe-
sion of particles in the nanometer size range depends 
mainly on van der Waals forces and not on key-lock con-
cepts as often incorrectly described [130]. Indeed, it has 
been shown that adhesion processes (which are based on 
van der Waals and other forces) may lead to phospholipid 
molecules of the membrane moving apart to let nanopar-
ticles enter into the cell passively [60]. Mathematically, 
these van der Waals forces can be described considering 
the work of adhesion, W, geometry, elasticity and forces 
applied to the system. Almost four decades ago, these 
forces interacting on the contact points of small parti-
cles were described by the JKR (Johnson Kendall Roberts) 
analysis, F  =  -3πWD/8, where D is the Hertz contact diam-
eter [131]. The measurement of these forces is possible by 
applying Atomic Force Microscopy (AFM) [132]. The inter-
particle forces both for nanoparticles and virus particles 
are very small and are in the order of thermal diffusion 
forces. Measurements of self-adhesion forces leading to 
doublet and triplet formation showed very similar results 
for polystyrene and virus particles [133]. Proteins can 
accelerate adhesion between particles/viruses and cells 
and measurements of this process have revealed a step-
wise process, giving evidence of several adhesive states, 
with significant energy barriers between these states that 
in fact allow catalytic actions to accelerate the kinetic pro-
cesses leading to contact.
Theoretical models have moved from trivial and inac-
curate lock-and-key-models to the more physically relevant 
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van der Waals principles. On the scale of such models, 
Brownian motion cannot be neglected and thereby adhe-
sion becomes a statistical process leading to a dynamic 
equilibrium that depends on concentration, thermal 
energy and the attractive potential. Further research into 
adhesion and molecular dynamics modelling will allow 
improved visualization and understanding of the molec-
ular basis of adhesion processes. A recently presented 
experimental procedure showed that nanoparticles can 
be functionalized with appropriate ligands to render them 
membrane-permeant [80]. Recent characterization of the 
trafficking mechanisms of prion proteins and certain bac-
teria may present new paradigms for understanding how 
nanoparticles could enter cells [60, 134].
Nanoparticle interactomes: 
emerging systems biology 
approaches in nanotoxicology
Systems biology is an emerging field which seeks to inte-
grate high-throughput biological studies to understand 
how biological systems function [135, 136]. By studying the 
relationships and interactions between various parts of a 
biological system (e.g., metabolic pathways, organelles, 
cells, physiological systems, organisms, etc.) it is hoped 
that eventually an understandable model of the whole 
system can be developed. One successful approach has 
been to determine protein interactomes, which are maps 
or networks connecting a protein to all the other proteins 
with which it interacts directly or indirectly [137, 138]. 
This is possible for proteins, as they must interact with 
other molecules in order to fulfil their biological roles. For 
instance, enzymes, receptors, and transcription factors 
have to bind their substrates, ligands, and target DNA 
elements, respectively, to execute their function. Thus, 
removal of one protein will affect the functioning of other 
proteins, which will in turn affect the functioning of other 
proteins in a complex network functioning.
Small changes in a protein conformation, such as may 
be induced by interaction with the surface of a nanopar-
ticle (both engineered and combustion derived) [21], can 
potentially have large impacts on a protein’s function, 
as well as its interaction with other proteins and in this 
way affect their function. Thus, introduction of nanopar-
ticles into living systems can affect a whole series of inter-
related processes, simply by altering the behaviour of one 
or two key proteins, which in turn affects the protein-pro-
tein interactions. This sort of network type behaviour is 
referred to as a protein’s interactome, and an example of 
such a connectivity diagram for a nanoparticle-induced 
toxicity pathway is shown in Figure 4. Thus, a key chal-
lenge for the future is to identify the protein networks that 
are affected by introduction of different nanoparticles, 
and in this way to determine the nanoparticles’ interac-
tome, and connect this to the nature of the nanoparticles’ 
bio-nano interface.
Towards predicting  nanoparticle fate 
and behavior in living organisms 
based on the bio-nano interface
If the bio-nano interface is what is actually seen by, and 
interacts with, organisms, then in principle, mapping 
and reading a large number of nanoparticle bio-nano 
interfaces could provide a mechanism for grouping and 
classification of nanomaterials, and indeed even for pre-
dicting nanoparticle fate and behaviour in the future 
based on the initial bio-nano interface at the point of 
first contact with a biological system. There is a need for 
advanced methodologies to study nanoparticles in situ in 
biofluids, and to understand the packing rules and ori-
entational drivers for specific proteins and other biomol-
ecules to locate at the bio-nano interface, and from this 
to understand nanoparticle interactomes, or networks 
of signalling molecules that can be triggered by different 
bio-nano interfaces.
It is clear that the final cellular location of a nanoparti-
cle will determine the range of cellular pathways and pro-
cesses that the particle can potentially trigger or disrupt, 
and thus reaching different intracellular locations leads to 
different potential functional responses. Once the nano-
particle characteristics can be connected to the nature of 
the biomolecule layer adsorbed onto the particle, i.e., the 
bio-nano interface, and the details of the surface exposed 
peptides or amino acid groups available for interaction 
with endogenous machinery and other biomolecules, the 
details of the bio-nano interface can be correlated to the 
biological responses resulting from the presence of the 
nanoparticle in vivo.
However, characterising the nature of the nanopar-
ticle corona and the bio-nano-interface is not a trivial 
task. The recent review by Saptarshi et al. [140] provides 
a table summarising the approaches that have been uti-
lised in the recent literature to study nanoparticle-protein 
interactions, with a focus on methods to assess nanopar-
ticle surface driven protein conformational changes and 
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uptake of nanoparticles by cellular structures. An earlier 
review included a more diverse set of approaches, includ-
ing ones routinely used for assessment of protein-protein 
interactions, including NMR, phage display libraries, 
limited proteolysis and many others [141]. An elegant 
paper by Cukalevski et al. demonstrates that nanoparticle 
surface charge is a critical parameter for predicting struc-
tural changes in adsorbed proteins, as circular dichroism, 
fluorescence spectroscopy, and limited proteolysis experi-
ments indicated effects on both secondary and tertiary 
structures, with the effect being specific for each protein 
studied [21]. Use of advanced imaging approaches such as 
Raman microscopy can provide important insights regard-
ing the impact of a bio-corona (e.g., using surface-grafted 
adenosine triphosphate (ATP) as a model of a corona 
formed in alveolar liquid) on nanoparticle uptake and 
the fate of the nanoparticles and the protein corona [142]. 
Raman microscopy unambiguously showed that magnet-
ite nanoparticles are internalized within A549 cells after 
24  h co-incubation, and that the ATP ligand is retained 
on the nanoparticles throughout the uptake process [142]. 
Other important approaches include Fluorescence Corre-
lation Microscopy which can be used to study the protein 
organisation in the corona such as the number of proteins, 
and whether a monolayer or multi-layer forms and even 
provides information about the residence time of proteins 
(although at present limited to single proteins studies) 
[143], and of course the recent advances in proteomics 
approaches (e.g., label-free snapshot proteomics) applied 
to nanoparticles allow quantitative and time-resolved 
assessments of amount and composition of proteins in 
nanoparticle coronas [144]. While significant progress is 
being made, the experimental approaches employed by 
many studies currently involve detailed study of a single 
protein with the nanoparticle surface rather than the 
complete biofluids studies where significant competitive 
and cooperative binding effects come into play. Addi-
tional method development, or optimisation of methods 
to address and fully characterise dynamic nanoparticle 
bio-nano-interfaces is required.
Given that it is the nature of the adsorbed protein 
coating that determines uptake and intracellular traffick-
ing of nanoparticles, in principle, one can begin to think 
of designing nanoparticles to adsorb specific proteins in 
order to determine the final cellular location of the nano-
particles. In principle, we should be able to “post” a nano-
particle to anywhere in the cell, simply using the bio-nano 
interface which will be “read” by the cellular machinery, 
and direct the nanoparticle to the desired location accord-
ing to the instructions “printed” on the nanoparticle 
surface, via the bio-nano interface. By understanding 
the nature of the bio-nano interface that leads to locali-
sation in specific intracellular locations, versus recycling 
out of cells, tissues or organs, it may be possible to design 
nanoparticles that acquire such coatings spontaneously, 
leading to nanomaterials that are safe by design [145] of 
their bio-nano interface.
Bio-nano interface based structure-
activity relationships?
Nanoparticle uptake, intracellular trafficking and cellu-
lar response mechanisms have been extensively studied 
in vitro. Although the extent to which results of in vitro 
models are translatable to in vivo exposures is debate-
able, such models potentially provide a basis for rapid 
screening of potential toxicants or nanobased medical 
treatments and also provide an insight into cellular 
interactions of nanoparticles. Furthermore, Directive 
2010/6386/609/EU on the protection of animals used for 
experimental and other scientific purposes indicates 
that the EU Commission and the member states should 
actively support the development, validation and accept-
ance of methods which could reduce, refine or replace 
the use of laboratory animals (3Rs). However, given the 
myriad of nanoparticle types, each potentially with vari-
able chemical functionalisations and sizes, and each of 
which can present a different bio-nano interface depend-
ing on the exposure conditions (media pH, ionic strength, 
biomolecule composition, etc.), and given the similarly 
huge number of cell types and lines, purported to repre-
sent target organs in vivo, the route towards Quantitative 
Structure Activity Relationships (QSARs) is not clear. In 
toxicology, responses are commonly classified in terms 
of effective concentrations which elicit an endpoint of an 
in vitro or in vivo assay, but, for a given nanoparticle, sig-
nificant variations can be seen between different assays 
and cell lines. It is therefore important to identify critical 
points and rates of interaction between nanomaterials 
and biological signalling pathways, most notably via the 
bio-nano interface, and identify routes towards estab-
lishing quantifiable parameters governing the activity of 
nanoparticles and their structural dependences. A novel 
biological surface adsorption index (BSAI) for nanoparti-
cles that was proposed for use to predict the “biological 
identity” of nanoparticles (see Figure 5) could serve as a 
useful descriptor in modelling of nanoparticle structure-
activity relationships [139]. Notably, consideration should 
be given to both acute and chronic effects, and indeed to 
the potential for novel other end-points (not yet identified 
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within the scope of OECD2 or other approaches), such 
as the influence of nanoparticles on protein fibrillation 
in situ, and the frustrated phagocytosis caused by high 
aspect ratio nanomaterials such, as carbon nanotubes, 
identified in the SCENIHR Opinion on Risk Assessment 
of Products of Nanotechnologies [146]. Indeed, it is worth 
reiterating that even now there is no simple toxicity assay 
or combination of assays that could predict mesotheli-
oma, the asbestos-induced cancer [147].
Conclusions and recommendations 
for researchers
This review paper has described some of the key research 
towards understanding the role of the layer of adsorbed 
biomolecules (the biomolecule corona) on the fate and 
behaviour of nanoparticles upon contact with living 
systems. We have focussed the existing data and knowledge 
around four key concepts to demonstrate the central role of 
the bio-nano interface for understanding, and eventually 
predicting, nanoparticle interactions, impact and safety. 
These four concepts are: Coating, Translocation, Signalling 
and Kinetics. As demonstrated by the degree of cross-ref-
erencing between the concepts, each is closely linked with 
the others and can only be fully understood in light of the 
others. Based on the above discussions, a number of key rec-
ommendations for researchers have been drawn, to help in 
the framing of future experimental approaches, as follows:
1. Recognise that nanoparticles cannot be treated 
(regulated) as non-interacting species, but rather 
must be thought of, and studied as, biological entities, 
which interact with proteins and other molecules 
in the (micro)environment and are influenced by 
this biomolecule interface in all their subsequent 
interactions with organs, tissues cells, intracellular 
organelles. Thus, the key parameter to understand 
nanoparticle interactions with living systems and their 
biological impacts, becomes the nature, composition, 
organisation and structure, and evolution of the bio-
nano interface [42], which is a consequence of their 
physico-chemical parameters and the nature of the 
biological microenvironment [54].2 Organisation for Economic Cooperation and Development.
Nanoparticle adsorption sites
Nanoparticle
core
Small molecules
Solid-liquid interface
Corona-media
interface
Amino-acid residues
Plasma proteinsSmall moleculesNanoparticles
Figure 5 Illustration of the competitive adsorption of small molecules and proteins onto the surface adsorption sites of nanoparticles. Left: 
in a physiological environment, nanoparticles are exposed to different proteins and small molecules. Right: the competitive adsorption of 
small molecules (upper) and the amino-acid residues of proteins (lower) on a nanoparticle. The orange ring on the nanoparticle with blue 
irregular shapes represents the adsorption sites that are not uniformly distributed on the nanoparticle surface. Small molecules with known 
molecular descriptors [R, π, α, β, V] can be used as probes to measure the molecular interaction strengths of the nanoparticles with small 
molecules and biomolecules. From reference [139]. Note that the particles, small molecules and proteins are not drawn to scale.
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 In its simplest manifestation, this then suggests 
that studies of nanoparticle interactions with living 
systems should include as standard characterisation 
of the nanomaterials size, size distribution, surface 
charge as a minimum in the dispersion medium in 
which they will be exposed to the test species. Some 
visualisation of the agglomeration state should also 
be included where possible, such as Electron Micro-
scopy imaging coupled with, for example, Differ-
ential Centrifugation Sedimentation, which reports 
on the distribution of particle monomers, dimers, 
trimers and larger aggregates in complex biofluids 
[5]. Research Infrastructures such as FP7-QualityNano 
(www.qualitynano.eu) are an important mecha-
nism to provide access to such methodologies to the 
nanosafety research community.
 A more advanced manifestation of this requires the 
development of new tools and approaches to character-
ise the bio-nano interface in detail, including mapping 
the outermost peptide sequences of the proteins con-
tained in the nanoparticle-corona, as it is these amino 
acid sequences that will be available to engage with 
biological machinery. Depending on the orientation 
of proteins in the corona, and their degree of unfold-
ing, new or so-called “cryptic” presentations of amino 
acids could result from protein binding to nanoparti-
cles, resulting in the potential for new protein-protein 
interactions and/or altered signalling [140, 141, 148].
2. Recognise the central role of the bio-nano interface as 
the determinator of nanoparticle fate and behaviour 
in the environment and in humans, and frame studies 
in a manner that connects uptake and impacts to bio-
nano interface and its signalling interactome, i.e., 
the full set of other biomolecules that interact with 
the biomolecules at the bio-nano interface and the 
signalling implications of these.
 This also requires a reassessment of how we design in 
vitro experiments to be representative of in vivo condi-
tions, and to allow in vitro-in vivo correlations, taking 
account of the fact that quite different bio-nano inter-
faces can result from different mass transport, kinetic 
and concentration regimes. Thus, the 3–10% serum 
and stationary (steady-state) conditions typical of in 
vitro experiments may not be fully suitable to predict 
the bio-nano interface and the consequent impacts 
from the same nanomaterials subject to interstitial or 
vascular flow rates and protein concentrations typical 
in vivo (55–80% protein).
3. Consider a framework for classification of 
nanomaterials based on the details of their bio-nano 
interface and its stability, evolution and degradation 
rather than one based solely on underlying physico-
chemical properties. In this way, direct connections can 
be made with potential for bioaccumulation, potential 
for degradation, and other more direct toxicities in 
addition to allowing more subtle effects from perturbed 
signalling pathways to emerge. It will also enable 
issues such as opsonisation and immunogenicity, and 
the potential for nanomaterials to modulate protein 
fibrillation to be addressed as part of the assessment 
process. Important steps here will include a detailed 
understanding of the conditions under which 
nanoparticle exocytosis may occur, and how signals 
for exocytosis could be “designed” into the bio-nano 
interface, in first steps towards safety by design.
Acknowledgements: This paper is based on inputs col-
lected for the nano-bio interactions chapter of the Euro-
pean Nanosafety Cluster Strategic Research Agenda 
(coordinated by Prof. Kai Savolainen, Finnish Institute 
of Occupational Health, Helsinki). IL acknowledges the 
stimulating discussions with her former colleagues at 
the Centre for BioNano Interactions at University College 
Dublin. Funding from the QualityNano project http://
www.qualitynano.eu, financed by the European Commu-
nity Research Infrastructures under the FP7 Capacities 
Programme (Grant No. INFRA-2010-262163), is gratefully 
acknowledged (IL). ACG received support from the Fonds 
National de la Recherche (FNR) of Luxembourg within the 
project NanEAU II (FNR/10/SR/825684). DB is funded by 
the EU grants PRD College (GA 223581), NanoTOES (GA 
264506), and HUMUNITY (GA 316383), and by a grant of 
The Fondazione Cariplo 2011-2014. BF is funded, in part, 
by the Swedish Research Council for Environment, Agri-
cultural Sciences and Spatial Planning (FORMAS), and the 
FP7 grant NANOSOLUTIONS (GA 309329). AA acknowl-
edges funding from: FP7 InLiveTox (228625), ReLiver 
(304961) and the Italian Ministry of Education, University 
& Research (MIUR) (Project PRIN 2010, MIND).
Received May 30, 2013; accepted October 29, 2013
References
1. Lynch I, Cedervall T, Lundqvist M, Cabaleiro-Lago C, Linse S, 
Dawson KA. The nanoparticle-protein complex as a biological 
entity; a complex fluids and surface science challenge for the 
21st century. Adv Colloid Interface Sci 2007;134–135:167–74.
212      Lynch et al.: The bio-nano interface: Towards safety by design
2. Cedervall T, Lynch I, Lindman S, Nilsson H, Thulin E, Linse S, 
et al. Understanding the nanoparticle-protein corona using 
methods to quantify exchange rates and affinities of proteins 
for nanoparticles. Proc Nat Acad Sci 2007a;104:2050–5.
3. Walczyk D, Baldelli-Bombelli F, Campbell A, Lynch I, 
Dawson KA. What the Cell “Sees” in Bionanoscience. JACS 
2010;132:5761–8.
4. Stark WJ. Nanoparticles in Biological Systems. Angewandte 
Chemie International Edition 2011;50:1242–58.
5. Dawson KA, Anguissola S, Lynch I. The need for in situ charac-
terisation in nanosafety assessment: funded transnational 
access via the QNano research infrastructure. Nanotoxicology 
2013;7:346–9.
6. Schürch S, Gehr P, Im Hof V, Geiser M, Green F. Surfactant 
displaces particles toward the epithelium in airways and alveoli. 
Respir Physiol 1990;80:17–32.
7. Kendall M, Hutton BM, Tetley TD, Nieuwenhuijsen M, Wigzell E, 
Jones F. Investigation of fine atmospheric particle surfaces 
and lung lining fluid interactions using XPS. Appl Surf Sci 
2001;178:27–36.
8. Kendall M, Tetley TD, Wigzell E, Hutton B, Nieuwenhuijsen M, 
Luckham P. Lung lining liquid modifies PM2.5 in favour of 
particle aggregation: A protective mechanism. Am J Physiol: 
Lung 2002;282:L109–14.
9. Kendall M, Guntern J, Lockyer NP, Jones FH, Hutton BM, 
Lippmann M, et al. Urban PM2.5 surface chemistry and 
interactions with broncho-alveolar lavage fluid (BALF). J Inhal 
Tox 2004;16 (suppl. 1):115–29.
10. Kendall M, Brown L, Trought K. Molecular adsorption at particle 
surfaces: A PM toxicity mediation mechanism. J Inhal Tox 
2004;16 (suppl. 1):99–105.
11. Kendall M, Holgate S. Exposure, dose, translocation and 
impacts of engineered nanomaterials in humans. Respirology 
2012;17:743–58.
12. Kendall M. Fine airborne urban particles (PM2.5) sequester 
lung surfactant and amino acids from human lung lavage. Am J 
Physiol Lung Cell Mol Physiol 2007;293:L1053–8.
13. Meerasa A, Huang JG, Gu FX. Human serum lipoproteins 
influence protein deposition patterns on nanoparticle surfaces. 
ACS Appl Mater Interfaces 2013;5:489–93.
14. Yang S, Bar-Ilan O, Peterson RE, Heideman W, Hamers RJ, 
Pedersen JA. Influence of humic Acid on titanium dioxide 
nanoparticle toxicity to developing zebrafish. Environ Sci 
Technol 2013;47:4718–25.
15. Gasser M, Rothen-Rutishauser B, Krug HF, Gehr P, Nelle M, 
Yan B, et al. The adsorption of biomolecules to multi-walled 
carbon nanotubes is influenced by both pulmonary surfactant 
lipids and surface chemistry. J Nanobiotechnology 2010;8:31.
16. Park H, Grassian VH. Commercially manufactured engineered 
nanomaterials for environmental and health studies: Important 
insights provided by independent characterization. Environ 
Toxicol Chem 2010;29:715–21.
17. Quik JT, Lynch I, Van Hoecke K, Miermans CJ, De Schamphelaere KA, 
Janssen CR, et al. Effect of natural organic matter on cerium 
dioxide nanoparticles settling in model fresh water. Chemosphere 
2010;81:711–5.
18. Baalousha M, Manciulea A, Cumberland S, Kendall K, Lead JR. 
Aggregation and surface properties of iron oxide nanoparticles: 
influence of pH and natural organic matter. Environ Toxicol 
Chem 2008;27:1875–82.
19. Pelley AJ, Tufenkji N. Effect of particle size and natural 
organic matter on the migration of nano- and microscale 
latex particles in saturated porous media. J Colloid Interf Sci 
2008;321:74–83.
20. OECD, Series on the Safety of Manufactured Nanomaterials, 
No. 27, List of manufactured nanomaterials and list of endpoints 
for phase one testing of the sponsorship programme for the 
testing of manufactured nanomaterials: revision. ENV/JM/
MONO(2010)46 2010.
21. Cukalevski R, Lundqvist M, Oslakovic C, Dahlback B, Linse S, 
Cedervall T. Structural changes in apolipoproteins bound to 
nanoparticles. Langmuir 2011;27:14360–9.
22. Bailes J, Gazi S, Ivanova R, Soloviev M. Effect of gold 
nanoparticle conjugation on the activity and stability of 
functional proteins. Methods Mol Biol 2012;906:89–99.
23. Lesniak A, Fenaroli F, Monopoli MP, Aberg C, Dawson KA, 
Salvati A. Effects of the presence or absence of a protein corona 
on silica nanoparticle uptake and impact on cells. ACS Nano 
2012;6:5845–57.
24. Lesniak A, Campbell A, Monopoli MP, Lynch I, Salvati A, 
Dawson KA. Serum heat inactivation affects protein corona 
composition and nanoparticle uptake. Biomaterials 
2010;31:9511–8.
25. Maiorano G, Sabella S, Sorce B, Brunetti V, Malvindi MA, 
Cingolani R, et al. Effects of cell culture media on the dynamic 
formation of protein-nanoparticle complexes and influence on 
the cellular response. ACS Nano 2010;4:7481–91.
26. Linse S, Cabaleiro-Lago C, Xue W-F, Lynch I, Lindman S, Thulin E, 
et al. Nucleation of protein fibrillation by nanoparticles. PNAS 
2007;104:8691–6.
27. Wang Y, Li Y, Costanza J, Abriola LM, Pennell KD. 
Enhanced mobility of fullerene (C60) nanoparticles in 
the presence of stabilizing agents. Environ Sci Technol 
2012;46:11761–9.
28. Mahon E, Hristov DR, Dawson KA. Stabilising fluorescent silica 
nanoparticles against dissolution effects for biological studies. 
Chem Commun (Camb) 2012;48:7970–2.
29. Ge C, Du J, Zhao L, Wang L, Liu Y, Li D, et al. Binding of blood 
proteins to carbon nanotubes reduces cytotoxicity. Proc Natl 
Acad Sci USA 2011;108:16968–73.
30. Monopoli MP, Dorota Walczyk D, Lowry-Campbell A, Elia E, 
Lynch I, Bombelli FB, et al. Physical-chemical aspects of protein 
corona: relevance to in vitro and in vivo biological impacts of 
nanoparticles. J Am Chem Soc 2011;133:2525–34.
31. Casey A, Herzog E, Lyng FM, Byrne HJ, Chambers G,  
Davoren M. SWCNT suppress inflammatory mediator responses 
in human lung epithelium in vitro. Toxicol Lett 2008;179: 
78–84.
32. Salvati A, Pitek AS, Monopoli MP, Prapainop K, Bombelli FB, 
Hristov DR, et al. Transferrin-functionalized nanoparticles lose 
their targeting capabilities when a biomolecule corona adsorbs 
on the surface. Nat Nanotechnol 2013;8:137–43.
33. Damiano MG, Mutharasan RK, Tripathy S, McMahon KM, 
Thaxton CS. Templated high density lipoprotein nanoparticles 
as potential therapies and for molecular delivery. Adv Drug Deliv 
Rev 2012;65:649–62.
34. Lesniak A, Salvati A, Santos-Martinez MJ, Radomski MW, 
Dawson KA, Åberg C. Nanoparticle adhesion to the cell 
membrane and its effect on nanoparticle uptake efficiency. J Am 
Chem Soc 2013;135:1438–44.
Lynch et al.: The bio-nano interface: Towards safety by design      213
35. Shvedova AA, Kagan VE, Fadeel B. Close encounters of the small 
kind: adverse effects of man-made materials interfacing with 
the nano-cosmos of biological systems. Annu Rev Pharmacol 
Toxicol 2010;50:63–88.
36. Klein J. Probing the interactions of proteins and nanoparticles. 
Proc Natl Acad Sci USA 2007;104:2029–30.
37. Deng ZJ, Liang M, Toth I, Monteiro MJ, Minchin RF. Molecular 
interaction of poly(acrylic acid) gold nanoparticles with human 
fibrinogen. ACS Nano 2012;6:8962–9.
38. Cedervall T, Lynch I, Foy M, Berggård T, Donnelly SC, 
Cagney G, et al. Detailed Identification of Plasma Proteins 
Adsorbed on Copolymer Nanoparticles. Angew Chem Int Ed 
2007;46:5754–6.
39. Krug HF, Wick P. Nanotoxicology: an interdisciplinary challenge. 
Angewandte Chemie Internat Ed 2011;50:1260–78.
40. Rivera Gil P, Oberdörster G, Elder A, Puntes V, Parak WJ. 
Correlating physico-chemical with toxicological properties 
of nanoparticles: the present and the future. ACS Nano 
2010;4:5527–31.
41. Kendall M, Ding P, Kendall K. Particle and nanoparticle 
interactions with fibrinogen: the importance of aggregation in 
nanotoxicology. Nanotoxicology 2011;5:55–65.
42. Fadeel B, Feliu N, Vogt C, Abdelmonem AM, Parak WJ.  
Bridge over troubled waters: understanding the synthetic  
and biological identities of engineered nanomaterials.  
Wiley Interdiscip Rev Nanomed Nanobiotechnol 2013;5: 
111–29.
43. Savolainen KB, Brouwer D, Fadeel B, Fernandes T, Kuhlbusch T, 
Landsiedel R, et al. Nanosafety in Europe 2015–2025: Towards 
safe and sustainable nanomaterials and nanotechnology 
innovations. FIOH: Finland, 2013.
44. Lundqvist M, Stigler J, Cedervall T, Berggård T, Flanagan M, 
Lynch I, et al. The evolution of the protein corona around 
nanoparticles: a test study. ACS Nano 2011;5:7503–9.
45. Lacerda SH, Park J, Meuse C, Pristinski D, Becker ML, Karim A,  
et al. Interaction of gold nanoparticles with common human 
blood proteins. ACS Nano 2009;4:365–79.
46. Schulze C, Schaefer UF, Ruge CA, Wohlleben W, Lehr C-M. 
Interaction of metal oxide nanoparticles with lung surfactant 
protein A. EJPB 2010;77:376–83.
47. Kendall M, Ding P, Mackay R-M, Madsen J, Deb R,  
MacKenzie Z, et al. Surfactant protein D alters cellular  
uptake of particles and nanoparticles. Nanotoxicology 
2013;7:963–73.
48. Fleischer CC, Kumar U, Payne CK. Cellular binding of  
anionic nanoparticles is inhibited by serum proteins 
independent of nanoparticle composition. Biomater Sci 
2013;1:975–982.
49. Lundqvist M, Stigler J, Cedervall T, Elia G, Lynch I, Dawson K. 
Nanoparticle size and surface properties determine the protein 
corona with possible implications for biological impacts. PNAS 
2008;105:14265–70.
50. Schäffler M, Semmler-Behnke M, Sarioglu H, Takenaka S, 
Wenk A, Schleh C, et al. Serum protein identification and quanti-
fication of the corona of 5, 15 and 80 nm gold nanoparticles. 
Nanotechnology 2013;24:265103.
51. Jedlovszky-Hajdú A, Bombelli FB, Monopoli MP, Tombácz E, 
Dawson KA. Surface coatings shape the protein corona of 
SPIONs with relevance to their application in vivo. Langmuir 
2012;28:14983–91.
52. Amiri H, Bordonali L, Lascialfari A, Wan S, Monopoli MP, Lynch I, 
et al. Protein corona affects the relaxivity and MRI contrast 
efficiency of magnetic nanoparticles. Nanoscale 2013;5:8656–65.
53. Walkey CD, Chan WC. Understanding and controlling the 
interaction of nanomaterials with proteins in a physiological 
environment. Chem Soc Rev 2012;41:2780–99.
54. Yang ST, Liu Y, Wang YW, Cao A. Biosafety and bioapplication of 
nanomaterials by designing protein-nanoparticle interactions. 
Small 2013;9:1635–53.
55. Hyung H, Fortner JD, Hughes JB, Kim JH. Natural organic matter 
stabilizes carbon nanotubes in the aqueous phase. Environ Sci 
Technol 2007;41:179–84.
56. French RA, Jacobson AR, Kim B, Isley SL, Penn RL, Baveye PC. 
Influence of ionic strength, pH, and cation valence on 
aggregation kinetics of titanium dioxide nanoparticles. Environ 
Sci Technol 2009;43:1354–9.
57. Von Wandruszka R. The secondary structure of humic acid and 
its environmental implications. Washington, D.C.: US EPA, 1998.
58. Ogawara KF, Nagayama S, Minato K, Higaki K, Kai T, Kimura T. 
Pre-coating with serum albumin reduces receptor-mediated 
hepatic disposition of polystyrene nanosphere: implications 
for rational design of nanoparticles. J Control Release 
2004;100:451–5.
59. Lunov O, Syrovets T, Loos C, Beil J, Delacher M, Tron K, et al. 
Differential uptake of functionalized polystyrene nanoparticles 
by human macrophages and a monocytic cell line. ACS Nano 
2011;5:1657–69.
60. Geiser M, Rothen-Rutishauser BM, Kapp N, Schürch S, 
Kreyling W, Schulz H, et al. Ultrafine particles cross cellular 
membranes by non-phagocytic mechanisms in lungs and in 
cultured cells. Environ Health Perspect 2005;113:1555–60.
61. Rothen-Rutishauser BM, Kiama SG, Gehr P. A three-dimensional 
cellular model of the human respiratory tract to study the 
interaction with particles. Amer J Respir Cell Molec Biol 
2005;32:281–9.
62. Blank F, Gehr P, Rothen-Rutishauser B. Dendritic cells 
and macrophages form a transepithelial network against 
foreign particulate antigens. Amer J Respir Cell Molec Biol 
2007;36:669–77.
63. Blank F, Rothen-Rutishauser B, Schürch S, Gehr P. An optimized 
in vitro model of the respiratory tract wall to study particle cell 
interactions. J Aerosol Med 2006;19:392–405.
64. Kreyling WG, Semmler M, Erbe F, Mayer S, Takenaka S, Schultz J. 
Translocation of ultrafine insoluble iridium particles from lung 
epithelium to extrapulmonary organs is size dependent but very 
low. Toxicol Env Health Part A 2002;65:1513–30.
65. Kreyling WG, Semmler-Behnke M, Seitz J, Scymczak W, Wenk A, 
Mayer P, et al. Size dependence of the translocation of inhaled 
iridium and carbon nanoparticle aggregates from the lung of 
rats to the blood and secondary target organs. Inhal Toxicol 
2009;21(S1):55–60.
66. Gehr P, Green FH, Geiser M, Im Hof V, Lee MM, Schürch S. Airway 
surfactant, a primary defense barrier: mechanical and immuno-
logical aspects. J Aerosol Med 1996;9:163–81.
67. Ruge CA, Schaefer UF, Herrmann J, Kirch J, Cañadas O, 
Echaide M, et al. The interplay of lung surfactant proteins and 
lipids assimilates the macrophage clearance of nanoparticles. 
PLoS ONE 2012;7:e40775.
68. Hirn S, Semmler-Behnke M, Schleh C, Wenk A, Lipka J, 
Schäffler M, et al. Particle size-dependent and surface charge-
214      Lynch et al.: The bio-nano interface: Towards safety by design
dependent biodistribution of gold nanoparticles after intravenous 
administration. Eur J Pharm Biopharm 2011;77:407–16.
69. Kunzmann A, Andersson B, Thurnherr T, Krug HF, Scheynius A, 
Fadeel B. Toxicology of engineered nanomaterials: Focus on 
biocompatibility, biodistribution and biodegradation. Biochim 
Biophys Acta 2011;1810:361–73.
70. Kunzmann A, Andersson B, Vogt C, Feliu N, Ye F, Gabrielsson S, 
et al. Efficient internalization of silica-coated iron oxide 
nanoparticles of different sizes by primary human macrophages 
and dendritic cells. Toxicol Appl Pharmacol 2011;253:81–93.
71. Konczol M, Ebeling S, Goldenberg E, Treude F, Gminski R, 
Giere R, et al. Cytotoxicity and genotoxicity of sizefractionated 
iron oxide (magnetite) in A549 human lung epithelial cells: role 
of ROS, JNK, and NF-kappaB. Chem Res Toxicol 2011;24:1460–75.
72. Gao J, Xu B. Applications of nanomaterials inside cells. Nano 
Today 2009;4:37–51.
73. Treuel L, Xiue Jiang X, Nienhaus GU. New views on cellular 
uptake and trafficking of manufactured nanoparticles. J R Soc 
Interface 2013;10:20120939.
74. Limbach LK, Wick P, Manser P, Grass RN, Bruinink A, 
Stark WJ. Exposure of engineered nanoparticles to human 
lung epithelial cells: influence of chemical composition and 
catalytic activity on oxidative stress. Environ Sci Technol 
2007;41:4158–63.
75. Shapero K, Fenaroli F, Lynch I, Cottell DC, Salvati A, Dawson KA. 
Time and space resolved uptake study of silica nanoparticles by 
human cells. Mol Biosyst 2011;7:371–8.
76. Salvati AA, dos Santos T, Varela J, Pinto P, Lynch I, Dawson KA. 
Experimental and theoretical approach to comparative 
nanoparticle and small molecule intracellular import, 
translocation, and export. NanoMedicine 2011;7:818–26.
77. Higuchi Y, Wu C, Chang KL, Irie K, Kawakami S, Yamashita F, 
et al. Polyamidoamine dendrimer-conjugated quantum dots for 
efficient labeling of primary cultured mesenchymal stem cells. 
Biomaterials 2011;32:6676–82.
78. Han M, Kickhoefer VA, Nemerow GR, Rome LH. Targeted vault 
nanoparticles engineered with an endosomolytic peptide deliver 
biomolecules to the cytoplasm. ACS Nano 2011;5:6128–37.
79. Mukherjee SP, Lyng FM, Garcia A, Davoren M, Byrne HJ. 
Mechanistic studies of in vitro cytotoxicity of Poly(amidoamine) 
dendrimers in mammalian cells. Toxicol Appl Pharm 
2010;248:259–68.
80. Wang T, Bai J, Jiang X, Nienhaus U. Cellular uptake of 
nanoparticles by membrane penetration: a study combining 
confocal microscopy with FTIR spectroelectrochemistry. ACS 
Nano 2012;6:1251–9.
81. Brandenberger C, Müller C, Ali Z, Lenz A-G, Schid O, Parak WJ, 
et al. Quantitative evaluation of cellular uptake and trafficking 
of plain and polyethylene glycol-coated gold nanoparticles. 
Small 2010;6:1669–78.
82. dos Santos T, Varela J, Lynch I, Salvati A, Dawson KA. Effects 
of transport inhibitors on the cellular uptake of carboxylated 
polystyrene nanoparticles in different cell lines. PLoS One 
2011;6:e24438.
83. Ehrenberg MS, Friedman AE, Finkelstein JN, Oberdörster G, 
McGrath JL. The influence of protein adsorption on nanoparticle 
association with cultured endothelial cells. Biomaterials 
2009;30:603–10.
84. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, 
Koch-Brandt C, et al. Apolipoprotein-mediated transport of 
nanoparticle-bound drugs across the blood-brain barrier. J Drug 
Target 2002;10:317–25.
85. Kreuter J. Influence of the surface properties on nanoparticle-
mediated transport of drugs to the brain. J Nanosci 
Nanotechnol 2004;4:484–8.
86. Zaki NM, Tirelli N. Gateways for the intracellular access of 
nanocarriers: a review of receptor-mediated endocytosis 
mechanisms and of strategies in receptor targeting. Expert 
Opin Drug Deliv 2010;7:895–913.
87. Hillaireau H, Couvreur P. Nanocarriers’ entry into the cell: 
relevance to drug delivery. Cell Mol Life Sci 2009;66:2873–96.
88. Lin A, Sabnis A, Kona S, Nattama S, Patel H, Dong JF, et al. 
Shear-regulated uptake of nanoparticles by endothelial cells 
and development of endothelial-targeting nanoparticles. J 
Biomed Mater Res A 2010;93:833–42.
89. Vincent A, Babu S, Heckert E, Dowding J, Hirst SM, Inerbaev 
TM, et al. Protonated nanoparticle surface governing ligand 
tethering and cellular targeting. ACS Nano 2009;3:1203–11.
90. Sandin P, Fitzpatrick LW, Simpson JC, Dawson KA. High-speed 
imaging of rab family small gtpases reveals rare events in 
nanoparticle trafficking in living cells. ACS Nano 2012;6: 
1513–21.
91. Jin H, Heller DA, Strano MS. Single-particle tracking of 
endocytosis and exocytosis of single-walled carbon nanotubes 
in NIH-3T3 cells. Nano Lett 2008;8:1577–85.
92. Chithrani BD, Chan WC. Elucidating the mechanism of cellular 
uptake and removal of protein-coated gold nanoparticles of 
different sizes and shapes. Nano Lett 2007;7:1542–50.
93. Hirano S. A current overview of health effect research on 
nanoparticles. Environ Health Prev Med 2009;14:223–5.
94. Schins RP, Knaapen AM. Genotoxicity of poorly soluble 
particles. Inhal Toxicol 2007;19(Suppl 1):189–98.
95. Chan JK, Vogel CF, Baek J, Kodani SD, Uppal RS, Bein KJ, et al. 
Combustion derived ultrafine particles induce cytochrome 
P450 expression in specific lung compartments in the 
developing neonatal and adult rat. Am J Physiol Lung Cell Mol 
Physiol 2013;304:L665–77.
96. Park KH, Chhowalla M, Iqbal Z, Sesti F. Single-walled carbon 
nanotubes are a new class of ion channel blockers. J Biol Chem 
2003;278:50212–6.
97. Vranic S, Boggetto N, Contremoulins V, Mornet S, Reinhardt 
N, Marano F, et al. Deciphering the mechanisms of cellular 
uptake of engineered nanoparticles by accurate evaluation of 
internalization using imaging flow cytometry. Part Fibre Toxicol 
2013;10:2.
98. Bhabra G, Sood A, Fisher B, Cartwright L, Saunders M, 
Evans WH, et al. Nanoparticles can cause DNA damage across a 
cellular barrier. Nat Nanotechnol 2009;4:876–83.
99. Sood A, Salih S, Roh D, Lacharme-Lora L, Parry M, Hardiman B, 
et al. Signalling of DNA damage and cytokines across cell 
barriers exposed to nanoparticles depends on barrier 
thickness. Nat Nanotechnol 2011;6:824–33.
100. Weyand B, von Schroeder HP. Altered VEGF-A and receptor 
mRNA expression profiles, and identification of VEGF144 
in foetal rat calvaria cells, in coculture with microvascular 
endothelial cells. Cell Biol Int 2013;37:713–24.
101. Nic Ragnaill M, Bramini M, Ye D, Couraud PO, Romero IA, 
Weksler B, et al. Paracrine signalling of inflammatory cytokines 
from an in vitro Blood Brain Barrier upon exposure to polymeric 
nanoparticles. Analyst. 2013 Nov 5. [Epub ahead of print].
Lynch et al.: The bio-nano interface: Towards safety by design      215
102. Oberdörster G, Oberdörster E, Oberdörster J. Nanotoxicology: 
an emerging discipline evolving from studies of ultrafine 
particles. Environ Health Perspect 2005;113:823–39.
103. McKim JM. Building a tiered approach to in vitro predictive 
toxicity screening: a focus on assays with in vivo relevance. 
Comb Chem High Throughput Screen 2010;13:188–206.
104. Lavelle C, Berry H, Beslon G, Ginelli F, Giavitto J-L, Kapoula Z, 
et al. From molecules to organisms: towards multiscale 
integrated models of biological systems. Theoretical Biology 
Insights 2008;1:13–22.
105. Bassingthwaighte JB, Chizeck HJ, Atlas LE. Strategies and 
tactics in multiscale modeling of cell-to-organ systems. Proc 
IEEE Inst Electr Electron Eng 2006;94:819–30.
106. Díaz-Zuccarini V, Lawford PV. An in-silico future for the 
engineering of functional tissues and organs. Organogenesis 
2010;6:245–51.
107. Xia T, Kovochich M, Brant J, Hotze M, Sempf J, Oberley T, et al. 
Comparison of the abilities of ambient and manufactured 
nanoparticles to induce cellular toxicity according to an 
oxidative stress paradigm. Nano Lett 2006;6:1794–807.
108. Shvedova AA, Pietroiusti A, Fadeel B, Kagan VE. Mechanisms 
of carbon nanotube-induced toxicity: focus on oxidative stress. 
Toxicol Appl Pharmacol 2012;261:121–33.
109. Mailloux RJ, Bériault R, Lemire J, Singh R, Chénier DR, 
Hamel RD, et al. The tricarboxylic acid cycle, an ancient 
metabolic network with a novel twist. PLoS One 2007;1:e690.
110. Ahamed M, Akhtar MJ, Siddiqui MA, Ahmad J, Musarrat J, 
Al-Khedhairy AA, et al. Oxidative stress mediated apoptosis 
induced by nickel ferrite nanoparticles in cultured A549 cells. 
Toxicology 2011;283:101–8.
111. Ge Y, Bruno M, Wallace K, Winnik W, Prasad RY. Proteome 
profiling reveals potential toxicity and detoxification 
pathways following exposure of BEAS-2B cells to engineered 
nanoparticle titanium dioxide. Proteomics 2011;11:2406–22.
112. Bexiga MG, Varela JA, Wang F, Fenaroli F, Salvati A, Lynch I, 
et al. Cationic nanoparticles induce caspase 3 and 7-mediated 
cytotoxicity in a human astrocytoma cell line. Nanotoxicology 
2011;5:557–67.
113. Wang F, Yu L, Salvati A, Dawson KA. The biomolecular corona is 
retained during nanoparticle uptake and protects the cells from 
the damage induced by cationic nanoparticles until degraded 
in the lysosomes. Nanomedicine 2013;S1549–9634:00182–2.
114. Mukherjee SP, Byrne HJ. Polyamidoamine dendrimer 
nanoparticle cytotoxicity, oxidative stress, caspase activation 
and infammatory response: experimental observation and 
numerical simulation. Nanomedicine: Nanotechnology, 
Biology, and Medicine 2013;9:202–11.
115. Tsai YY, Huang YH, Chao YL, Hu KY, Chin LT, Chou SH, et al. 
Identification of the nanogold particle-induced endoplasmic 
reticulum stress by omic techniques and systems biology 
analysis. ACS Nano 2011;5:9354–69.
116. Deng ZJ, Mingtao Liang M, Monteiro M, Toth I, Minchin RF. 
Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 
(CD11b/CD18) receptor activation and pro-inflammatory 
cytokine release. Nat Nanotechnol 2010;6:39–44.
117. Deng ZJ, Mortimer G, Schiller T, Musumeci A, Martin D, 
Minchin RF. Differential plasma protein binding to metal oxide 
nanoparticles. Nanotechnology 2009;20:455101.
118. Love SA, Haynes CL. Assessment of functional changes 
in nanoparticle-exposed neuroendocrine cells with 
amperometry: exploring the generalizability of 
nanoparticle-vesicle matrix interactions. Anal Bioanal Chem 
2010;398:677–88.
119. Nel A, Xia T, Mädler L, Li N. Toxic potential of materials at the 
nanolevel. Science 2006;311:622–7.
120. Parry MC, Bhabra G, Sood A, Machado F, Cartwright L, 
Saunders M, et al. Thresholds for indirect DNA damage across 
cellular barriers for orthopaedic biomaterials. Biomaterials 
2010;31:4477–83.
121. Kagan VE, Konduru NV, Feng W, Allen BL, Conroy J, Volkov Y, 
et al. Carbon nanotubes degraded by neutrophil myelop-
eroxidase induce less pulmonary inflammation. Nat Nano 
2010;5:354–9.
122. Dell’Orco D, Lundqvist M, Cedervall T, Linse S. Delivery success 
rate of engineered nanoparticles in the presence of the protein 
corona: a systems-level screening. Nanomed: Nanotech Bio 
Med 2012;8:1271–81.
123. Shannahan JH, Lai X, Ke PC, Podila R, Brown JM, Witzmann FA. 
Silver nanoparticle protein corona composition in cell culture 
media. PLoS One 2013;8:e74001.
124. Kneipp K, Haka AS, Kneipp H, Badizadegan K, Yoshizawa N, 
Boone C, et al. Surface-enhanced raman spectroscopy in 
single living cells using gold nanoparticles. Appl Spectrosc 
2002;56:150–4.
125. Kneipp J, Kneipp H, McLaughlin M, Brown D, Kneipp K. In 
vivo molecular probing of cellular compartments with gold 
nanoparticles and nanoaggregates. Nano Lett 2006;6: 
2225–31.
126. Kneipp J, Kneipp H, Rajadurai A, Redmond RW, Kneipp K. 
Optical probing and imaging of live cells using SERS labels. 
J Raman Spectrosc 2009;40:1–5.
127. Kneipp J, Kneipp H, Rice WL, Kneipp K. Optical probes for 
biological applications based on surface-enhanced Raman 
scattering from indocyanine green on gold nanoparticles. Anal 
Chem 2005;77:2381–5.
128. Kneipp J, Kneipp H, Wittig B, Kneipp K. Novel optical 
nanosensors for probing and imaging live cells. J Phys Chem C 
2010;114:7421–6.
129. Dorney J, Bonnier F, Garcia A, Casey A, Chambers G, Byrne HJ. 
Identifying and localizing intracellular nanoparticles using 
raman spectroscopy. Analyst 2012;137:1111–9.
130. Kendall K, Du S, Morris S, Sweet S. Virus concentration 
and adhesion measured by laser tracking. J Adhesion 
2010;86:1029–40.
131. Johnson KL, Kendall K, Roberts AD. Surface energy 
and the contact of elastic solids. Proc R Soc London 
1971;A324:301–13.
132. Rong W, Ding W, Mädler L, Ruoff RS, Friedlander SK. 
Mechanical properties of nanoparticle chain aggregates by 
combined AFM and SEM: isolated aggregates and networks. 
NanoLett 2006;6:2646–55.
133. Kendall K, Kendall M, Rehfeldt F. Adhesion of Cells, Viruses 
and Nanoparticles. Dordrecht, Heidelberg, London, New York: 
Springer, 2011.
134. Medina-Kauwe LK. “Alternative” endocytic mechanisms 
exploited by pathogens: new avenues for therapeutic delivery? 
Adv Drug Deliv Rev 2007;59:798–809.
135. Hood L, Heath JR, Phelps ME, Lin B. Systems biology and new 
technologies enable predictive and preventative medicine. 
Science 2004;306:640–3.
216      Lynch et al.: The bio-nano interface: Towards safety by design
136. Janes KA, Albeck JG, Gaudet S, Sorger PK, Lauffenburger 
DA, Yaffe MB. A systems model of signaling identifies a 
molecular basis set for cytokine-induced apoptosis. Science 
2005;310:1646–53.
137. Ito T, Chiba T, Yoshida M. Exploring the protein interactome 
using comprehensive two-hybrid projects. Trends Biotechnol. 
2001;19(10 Suppl):S23–7.
138. Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck FH, 
Goehler H, et al. A human protein-protein interaction network: 
a resource for annotating the proteome. Cell 2005;122:957–68.
139. Xia XR, Monteiro-Riviere NA, Riviere JE. An index for charac-
terization of nanomaterials in biological systems. Nat 
Nanotechnol 2010;5:671–5.
140. Saptarshi SR, Duschl A, Lopata AL. Interaction of nanoparticles 
with proteins: relation to bio-reactivity of the nanoparticle. 
J Nanobiotechnol 2013;11:26.
141. Lynch I, Dawson KA, Linse S. Detecting cryptic epitopes created 
by nanoparticles. Science Signaling 2006;2006:14.
142. Wilkinson K, Ekstrand-Hammarström B, Ahlinder L, Guldevall K, 
Pazik R, Kępiński L, et al. Visualization of custom-tailored iron 
oxide nanoparticles chemistry, uptake, and toxicity. Nanoscale 
2012;4:7383–93.
143. Röcker C, Pötzl M, Zhang F, Parak WJ, Nienhaus GU. A 
quantitative fluorescence study of protein monolayer 
formation on colloidal nanoparticles. Nat Nanotechnol 
2009;4:577–80.
144. Tenzer S, Docter D, Kuharev J, Musyanovych A, Fetz V, Hecht R, 
et al. Rapid formation of plasma protein corona critically 
affects nanoparticle pathophysiology. Nat Nanotechnol 
2013;8:772–81.
145. European Academies Science Advisory Council, E., and 
European Commission Joint Research Centre (JRC) Joint 
EASAC-JRC Report, September 2011; 2011.
146. Scientific Committee on Emerging and Newly Identified Health 
Risks SCENIHR Opinion on Risk Assessment of Products of 
Nanotechnologies; 2009.
147. van der Bij S, Schaake E, Koffijberg H, Burgers JA, de Mol BA, 
Moons KG. Markers for the non-invasive diagnosis of 
mesothelioma: a systematic review. Br J Cancer 2011;104: 
1325–33.
148. Lynch I. Are there generic mechanisms governing interactions 
between nanoparticles and cells? Epitope mapping the 
outer layer of the protein–material interface. Physica A 
2007;373:511–20.
